IUPUI CURRICULUM VITAE FORMATFOR PROMOTION AND TENURE DOSSIERS

NAME: MATHER Kieren JamesLast First Middle

Academic Office:Indiana University541 North Clinical Drive, Room CL365Indianapolis, IN 46202

Clinical Studies Office: Indiana University Clinical Research Center550 N University Blvd, Room 5550Indianapolis, IN 46202

EDUCATION: POSTDOCTORALInstitution Degree Date Awarded

See ‘Further Education’ below

GRADUATEInstitution Degree Date Awarded

University of Calgary, Calgary, Alberta, Canada. MD May 1992.

UNDERGRADUATEInstitution Degree Date Awarded

University of Calgary, Calgary, Alberta, Canada. BSc (Biochemistry) with distinction, June 1989.

FURTHER EDUCATION: (Advanced and Specialty Training, Fellowships, Institutes)Institution Credential Date Awarded

Indiana University, Indianapolis, Indiana, Postgraduate clinical research fellowship, USA. Dr Alain Baron. 1998 - 1999

University of Calgary, Calgary, Alberta, Canada. Postgraduate clinical research fellowship, Dr Todd Anderson 1996 – 1998

University of Calgary. Calgary, Alberta, Canada Endocrinology Fellowship,1993 - 1996

University of British Columbia, Vancouver, British Columbia, Canada General Internal Medicine (Core program), 1992 – 1993

1rev. Jan 2012

The Greater Victoria Hospital Society, Victoria, British Columbia, Canada. (Internship administered by The University of British Columbia, Vancouver, British Columbia, Canada).

Rotating Internship 1991 - 1992

APPOINTMENTS:ACADEMIC (i.e. academic appointments, including academic administrative roles)Institution Rank/Title Inclusive Dates

Indiana University School of Medicine Professor of Medicine July 2012-presentIndiana University School of Medicine. Associate Professor July 2007-June 2012

Tenured July 1 2008.Indiana University School of Medicine, Assistant Professor, Jan 2001 – June 2007.Indiana School of Medicine, Visiting Assistant Professor July 2000 - Dec 2000.

NON-ACADEMIC (i.e. administrative, hospital or corporate appointments, consultantships)Institution/Entity Title Inclusive Datesn/a

LICENSURE, CERTIFICATION, SPECIALTY BOARD STATUS (as applicable for discipline): Credential Number Inclusive Dates

ABIM (Endocrinology) 1998-2018. FRCPC (Endocrinology) 1998 FRCPC (Internal Medicine) 1997ABIM (Internal Medicine) 1996 - 2006.LMCC (National Licensure Exam Canada) 1994

Indiana State Medical License 01051373 1999 – presentAlberta, Canada. 011789. 1997 –1999.British Columbia, Canada. 14839. 1993 –1999.

PROFESSIONAL ORGANIZATION MEMBERSHIPS: Organization Inclusive Dates

Association for Patient Oriented Research 2005 - presentFederation of American Societies for Experimental Biology (FASEB) 2004 – presentAmerican Association for the Advancement Of Science 2002 - presentCentral Society for Clinical Research 2002 – presentAmerican Diabetes Association 1997 – present Canadian Diabetes Association 1996 – presentCanadian Society for Clinical Investigation 1998 – presentThe Endocrine Society 1997 – presentBritish Columbia Internal Medicine Society 1992 – 1999British Columbia Medical Association 1992 – 1999Canadian Medical Association 1989 – presentAlberta Medical Association 1989 – present

2rev. Jan 2012

PROFESSIONAL HONORS AND AWARDS: TEACHINGAward Name Granted By Date Awarded

Indiana University Trustees Teaching Award 2011Gold Star for Excellence in Lecturing (Endocrinology), 1999

RESEARCHAward Name Granted By Date Awarded

Member, American Society of Clinical Investigation, 2012Order of the Amaranth support for ADA Career Development Award, 2006-2007Indiana University School of Medicine Outstanding Junior Faculty Research Award, Department of Medicine 2005American Diabetes Association, Career Development Award 2005-2010GlaxoSmithKline Endocrinology and Metabolism Scholar Award 2004 American Diabetes Association, Junior Faculty Award 2002-2005Alberta Heritage Fund for Medical Research, Clinical Fellowship. 1998-2000

SERVICEAward Name Granted By Date Awarded

OVERALL/OTHERAward Name Granted By Date Awarded

Nat Christie Foundation Medical Entrance Award for Tuition and Fees. 1989, 1990 and 1991Joseph Albert Award for Elective Study at Centres of Excellence, 1991University of Calgary, Faculty of Science Gold Medal, 1989George I Drummond Memorial Award (Biochemistry), 1989.National Science and Energy Research Council of Canada summer studentship 1988Alberta Heritage Foundation for Medical Research summer studentship, 1987 and 1989Viscount Bennett Scholarship (Undergraduate Merit), 1987.University of Calgary Undergraduate Merit Award, 1987 PanCanadian Scholarship (Undergraduate Merit), 1985 to 1988Louise McKinney Post-Secondary Scholarship, 1986, 1988, and 1989University of Calgary Academic Scholarship for Freshmen, 1985

PROFESSIONAL DEVELOPMENT: List courses, workshops or training programs attended to enhance your performance in any area of academic work.Course/Workshop Title Provider Date

National MeetingsAmerican Diabetes Association Scientific Sessions 1999 -2012American Heart Association 1999 - 2004American Society of Clinical Investigation 2012

3rev. Jan 2012

The Endocrine Society National Meeting 2000–03, 2011-15

Regional Meetings Central Society for Clinical Research 2001 - 2015

Faculty Development ProgramsGrant writing seminar IUPUI 2004, 2010

LIBRARIAN PERFORMANCE:

n/a

TEACHING:

TEACHING ASSIGNMENTS: List the course number, brief title, format (i.e. lecture, lab, clinic, online); your role (course director, lecturer), year and term, enrollment and other information that specifically pertains to your discipline (i.e. contact hours, hours of lab instruction, time instructing students on wards or clinics, course-related advising.) Mean teaching evaluation scores may be included.

UNDERGRADUATECourse # Short Title Format Role Term Enrollment

GRADUATECourse # Short Title Format Role Term Enrollment

Introduction to Clinical Medicine II (2nd year core curriculum). Endocrinology component. Team teaching of core endocrinology, 2X1 hour presentations per year.

G805 Diabetes and Obesity – One-hour lecture per course year 2004, 2005,2010. Graduate level team-taught course for physiology, endocrinology and metabolism PhD students

93MI710 Scientific Basis of Clinical Therapeutics – 2 hours small group teaching per course year 2003-present. Clinical diabetes case studies.

POSTGRADUATECourse # Short Title Format Role Term Enrollment

Clinics and Clinical Teaching:Wishard Hospital General Endocrinology Clinic (16 hours/mo)Indiana Clinic Outpatient General Endocrinology (16 hours/mo)Inpatient consultation service attending 3 months/year (includes teaching rounds 5 days per week and bi-weekly case-based workshops; teaching average 1 fellow, 2 residents and 1 medical student)

CONTINUING EDUCATION

4rev. Jan 2012

Course # Short Title Format Role Term Enrollment

MENTORING: List mentoring activities that pertain to your discipline such as thesis or advisory committees, students on research rotations, postdoctoral fellows and visiting scholars, advisor to graduating students, mentor for peer and self-assessment review, faculty mentoring committees. Name the individual, identify your role and provide inclusive dates.Individual Role Inclusive Dates

PhD Committees:Abbas Conteh; MD/PhD program, Indiana University Department of Cellular and Integrative Physiology (Faculty supervisor Dr J Tune). Hemodynamic and molecular differences in the cardioprotective response to GLP-1 agonism in lean and obese Ossabaw swine.

Graduate Committee Member 2014 - 2016

Daniel Sassoon, BS; MD/PhD program, Indiana University Department of Cellular and Integrative Physiology (Faculty supervisor Dr J Tune). MicroRNA changes in response to GLP-1 agonism modify the response to ischemia in lean and obese Ossabaw swine.

Graduate Committee Member 2014 - 2016

Stacey Dineen, BS; PhD program, Indiana University Department of Cellular and Integrative Physiology (Faculty supervisor Dr M Sturek). Effects of the GLP-1 agonist, exenatide, on the sarco/endoplasmic reticulum calcium ATPase (SERCA) and ER stress in coronary smooth muscle cells. Graduate Committee Member 2013 - 2015

Saurabh Thosar, BS, PhD Program. Indiana University Department of Kinesiology (Faculty supervisor Dr J Wallace). Effects of Sedentary Time on Vascular Function

Graduate Committee Member 2012-2014

Chawla, Aarti BSc, PhD program. Indiana University Department of Cellular and Integrative Physiology (Faculty supervisor Dr M Sturek). Effects of AICAR on myocardial metabolism and ischemia tolerance in Ossabaw swine with and without PKARg3 mutations.

Graduate Committee Member 2011-2012

Steve Moberly BSc, MD/PhD program. Indiana University Department of Cellular and Integrative Physiology (Faculty supervisor Dr J Tune). Effects of GLP-1 on metabolism in ischemic and reperfused myocardium. Co-Mentor, MD/PhD program 2010 - 2012

Zachary Berwick, BSc. Indiana University Department of Cellular and Integrative Physiology (Faculty supervisor Dr J Tune). Molecular determinants of hemodynamic response to ischemia

Graduate Committee Member 2010-2012

Blair Johnson, MS. Indiana University Department of Kinesiology (Faculty supervisor Dr J Wallace). Effects of Resistance Exercise on Vascular Function

Graduate Committee Member 2009-2011

5rev. Jan 2012

Jaume Padilla MS. Indiana University Department of Kinesiology (Faculty supervisor Dr J Wallace). Nitrergic mechanisms underlying the vasodilator response to forearm ischemia.

Graduate Committee Member 2008-2010

Ryan Harris MS. Indiana University Department of Kinesiology (Faculty supervisor Dr J Wallace). Exercise modulation of fat-induced vascular dysfunction.

Graduate Committee Member 2007-2009

Reina Watanabe MS. Indiana University Department of Cellular and Integrative Physiology (Faculty supervisor Dr J Tune). Potassium channel regulation of coronary microvasculature in a pig model of insulin resistance. Exploratory translational project for measuring coronary potassium channel activity in human obesity (Institutional Award)

Graduate Committee Member 2007-2009

Clinical research teaching:Farah Meah (Fellow) – 60 hours 2014 - presentMarisa Fisher (Fellow) – 200 hours 2013 - presentMaysa Hussain (Resident) – 90 hours 2012 - presentJun Chung (MS4) – 95 hours Feb 2011 – August 2011Yash Patel (resident) – 520 hours Oct 2009 – 2011.MPH research projects. Seasonality and endothelium-dependent vasodilation, analyses of a diabetes prevention clinical trial dataset for planned secondary outcomes.Pooja Singal (fellow) – 200 hours Sep 2006 – 2010Resident research project. User-independent approach to measuring insulin sensitivity with hyperinsulinemic euglycemic clamps.Nancy Yoon (fellow) – 80 hours March 2006 – June 2008Medicine resident research project. Blood pressure response to systemic endothelin antagonism in lean, obese, and diabetic subjects.Emily Veeneman (fellow) – 150 hours September 2004 – June 2007Fellowship clinical research project – PET studies of myocardial blood flow regulation in lean and obese subjects.Prashant Vaishnayva – 400 hours Sep – Nov 2004Visiting medical student, lab-based project contributing to plasma analyses for studies of the effect of endothelin on skeletal muscle insulin resistance in obese humans.Inessa Gelfand (fellow) – 150 hours December 2003 – presentFellowship clinical research project investigating the application of repaglinide to the clinical care of patients with cystic fibrosis-related diabetes mellitus.Lori Brame (fellow) – 200 hours April 2003 – June 2004Training in all aspects of clinical research including study design, procedures, data collection and assessment, statistical analysis and presentation of results in oral and written formats.Amale Lteif (fellow) - >1000 hours Aug 2001-June 2003Training in all aspects of clinical research, including bedside procedures, data collection and data assessment, statistical analysis, and presentation of results in both oral and written form.Bahram Mirzamohammadi (fellow)- 40 hours July 2000 – Jan 2001Training in all aspects of clinical research, including bedside procedures, data collection and data assessment, statistical analysis, and presentation of results in both oral and written form.

6rev. Jan 2012

TEACHING ADMINISTRATION AND CURRICULUM DEVELOPMENT: n/a

GRANTS/FELLOWSHIPS IN TEACHING: n/a

INVITED PRESENTATIONS – TEACHINGn/a

RESEARCH/CREATIVE ACTIVITY:

GRANTS/FELLOWSHIPS IN RESEARCH: Organize grants to differentiate active from pending/under review. Include your history of past grant support. If a record of effort to obtain funding is expected in your discipline and/or rank, include proposal submitted but not funded.ACTIVE RESEARCH GRANTS/FELLOWSHIPSTitle Granting Agency Role % Effort Amount Dates

COMPLETED RESEARCH GRANTS/FELLOWSHIPSTitle Granting Agency Role % Effort Amount Dates

PENDING RESEARCH GRANTS AND FELLOWSHIPSTitle Granting Agency Role % Effort Amount Dates

SUBMITTED BUT NOT FUNDED RESEARCH GRANTS/FELLOWSHIPSTitle Granting Agency Role % Effort Amount Dates

INVITED PRESENTATIONS – RESEARCHLOCALTitle Organization Date

Role of Endothelin in Insulin Action American Diabetes Association 2003Hormonal control of vascular function Endocrinology Division Grand Rounds 2005Approaches to measuring in vivo metabolism

Endocrinology Division Grand Rounds 2008GLP-1 and Myocardial Fuel Selection Endocrinology Division Grand Rounds 2011Diabetes treatments and heart disease Cardiology Division Grand Rounds 2012

REGIONALTitle Organization Date

NATIONALTitle Organization DateVascular Function and Cardiovascular Risk in Diabetes Mellitus. Clinical Update, May 2000, University of Calgary Continuing Medical Education.

7rev. Jan 2012

Insulin resistance, endothelin, and vascular dysfunction in obesity and diabetes. Grand Rounds, University of Oklahoma, Oklahoma City OK. May 2005.Endothelin in vascular and metabolic dysfunction in insulin resistance. Cardiology grand rounds, University of Kentucky, Knoxville KY. February 2007.Renal Disease and the Metabolic Syndrome American Society of Nephrology 2007 Annual Meeting. November 2007The Endocrine Society Diabetes Diagnosis and Management Day, 2011-14. Co-Director.Cardiovascular Benefits of GLP-1: Fact or Fantasy. Physiology Seminar, University of Mississippi, Sept 2014

INTERNATIONALTitle Organization DateEndothelial Function in the Polycystic Ovary Syndrome. 1st Virtual Congress of Endocrinology, Brazil. January 2001. http://www.endocrinologia.org.brInsulin Resistance, Metabolic Syndrome and Vascular Diseases: Update on Mechanistic Linkages. Canadian Vascular Biology Working Group, Vancouver. Aug 2003.Role of Insulin in Vascular Health. Korean Diabetes Society 2007 Annual Meeting. Pusan, Korea. November 2007GLP-1 based treatments for diabetes. Mexican Internal Medicine society 2010 Annual Meeting August 2010.

SERVICE:

Distinguish between service to the University and service to your professional discipline. If a service activity spans academic levels (i.e. Department, School, Campus, University) list it once. Identify your role in leadership (i.e. member, co-chair, chair).

UNIVERSITY SERVICE:DEPARTMENTActivity Role Inclusive DatesIU School of Medicine Promotion and Tenure Committee 2014 - present

SCHOOLActivity Role Inclusive DatesIU-CTSI Clinical Research Committee Oversight Committee 2008 - present

CAMPUSActivity Role Inclusive DatesIUPUI Institutional Review Board Member 2005-2012

UNIVERSITYActivity Role Inclusive Dates

IUPUI Research Support Fund Grant reviewer 2006 – 2012IU-CTSI Preclinical Development Team Project review 2009 - 2012IU-CTSI Concepts to Clinic Project Development Team 2013 – presentIU-CTSI Peer Review and Mentoring Committee – Obesity and Metabolic Diseases 2014-present

8rev. Jan 2012

PROFESSIONAL SERVICE: LOCALOrganization Activity Inclusive Dates

REGIONALOrganization Activity Inclusive Dates

Midwest Branch of the American Federation for Medical Research, Board Member, 2005 - 2007.Midwest Branch of the American Federation for Medical Research, Treasurer, 2008 - 2011.Midwest Branch of the American Federation for Medical Research, President Elect 2011-2012Midwest Branch of the American Federation for Medical Research, President 2012 - 2013

NATIONALOrganization Activity Inclusive Dates

American Federation for Medical Research, Council Member, 2002-present.Central Society for Clinical Research, Subspecialty Representative (Endocrinology) 2008-2010Endocrine Society Special Programs Committee 2009-2012American Diabetes Association Scientific Sessions Planning Committee 2014

Scientific review (National Service)

Reviewer: Circulation, Clinical Chemistry, Clinical Endocrinology, Hypertension, American Journal of Hypertension, American Journal of Physiology, European Journal of Clinical Nutrition, Metabolism, Cardiovascular Medicine, Diabetes, Diabetes Care, Hormones & Metabolism Research, Journal of the American College of Cardiology, Journal of Clinical Endocrinology and Metabolism, Journal of Clinical Sports Medicine, Journal of Diabetes Complications, Vascular Health and Risk Management, Endocrine Practice.

Editorial Board: Current Diabetes Reviews, Journal of Clinical Endocrinology & Metabolism.

Associate Editor: Journal of clinical Endocrinology & Metabolism 2012 – 14; Reviews in Endocrinology 2012 – present; Journal of Diabetes and its Complications 2014 – present.

Grant Review Boards (National Service)American Diabetes Association, Scientific Grant Review Board. Ad hoc member, 2002. Member, 2002-2009. Ad hoc reviewer, NIDDK Special Emphasis panel “Cardiovascular studies in Type 2 Diabetes – Ancillary studies” July 2007-Oct 2008Ad hoc reviewer, NHLBI Clinical and Integrative Cardiovascular Science (CICS) study section, October 2007-presentAd hoc reviewer, NHLBI Respiratory Integrative Biology and Translational Research (RIBT) study section, October 2009Ad hoc reviewer, NIDDK Clinical and Integrative Studies of Diabetes and Obesity (CIDO), October 2009-presentAd hoc reviewer, NHLBI Program Project Grant program 2009, 2010Ad hoc reviewer, NIDDK Special Emphasis Panel 2013, 2014, 2015

9rev. Jan 2012

Ad hoc reviewer, West Virginia CTSI Pilot Program Fund 2013

INTERNATIONALOrganization Activity Inclusive Dates

Diabetes UK Grant Review Board. Ad hoc member, 2006, 2009, 2015Dutch Diabetes Foundation Grant Review Board. Ad hoc member, 2006.University of Tasmania, Department of Biochemistry. Thesis review panel, Carolyn Kolka PhD candidate, (defense September 2006).University of Tasmania, Department of Biochemistry. Thesis review panel Carol Bussey PhD candidate, (defense May 2011).Belgian Diabetes Association Grant Review 2013Singapore National Medical Research Council 2014

PATIENT CARE/CLINICAL SERVICE: List activities in service to patients, indicating position, clinical venue and inclusive dates. Include role in administrative, organizational and team activities that improve the environment for clinical care. If the activities extend beyond the local level, indicate the sphere or extent of impact (i.e. regional, national, international).

Inpatient Consultation Service Attending at University and Wishard Hospitals 2 months/yearGeneral Endocrinology Clinic, Wishard Hospital, 1 half-day per weekGeneral Endocrinology Clinic, Medical Diagnostics Center, Indiana University Hospital. 1 half-day per weekTotal time devoted to patient care: 20%

GRANTS/FELLOWSHIPS IN SERVICE: Organize grants to differentiate active from pending/under review. Include your history of past grant support. If a record of effort to obtain funding is expected in your discipline and/or rank, include proposal submitted but not funded. ACTIVE SERVICE GRANTS/FELLOWSHIPS

National Institutes of Health. Cardiovascular Effects of GLP-1 in Obesity/Metabolic Syndrome. (R-01) 1/2013 – 11/2017 $3,370,060. (KierenMather, Co-Principal Investigator with Johnathan Tune PhD). 30% effort.

National Institutes of Health. Glycemia Reduction Approaches in Diabete: A Comparative Effectiveness Study (GRADE). (U-01). 12/2013 – 7/2017. $1,536,988. (Kieren Mather, Principal Investigator). 20% Effort

National Institutes of Health. Preservation of Beta Cell Function in Prediabetes/Early Type 2 Diabetes. (DP-3) 9/2011 – 8/2016. $3,829,033. (Kieren Mather, Principal Investigator). 30% effort.

Novo Nordisk Investigator-Initiated Studies Program. Effects of Liraglutide on Human Myocardial Metabolism. 7/2011 – 6/2012. $200,000 (Kieren Mather, Principal Investigator). 5% effort.

National Institutes of Health, Diabetes Prevention Program Outcomes Study, $2,950,100; 2002-2013 (David Marrero, Ph.D., Principal Investigator) 5% effort

COMPLETED SERVICE GRANTS/FELLOWSHIPS

10rev. Jan 2012

National Institutes of Health. Modulation of Human Myocardial Metabolism by GLP-1. (R21 HL092799) 12/2009 – 11/2011. $416,000 (Kieren Mather, Principal Investigator). 20% effort. No-cost extension to 11/2012.

National Institutes of Health. Non-invasive Assessment of Insulin Resistance. (SBIR Phase 2: R43 DK072637) Subcontract with BioChem Analysis Corporation. $45,789. 2009-2012 (Kieren Mather, Principal Investigator for subcontract) 5% effort

National Institutes of Health. Targeting Inflammation using Salsalate for Type 2 diabetes (TINSAL-T2D). (U-01) Subcontract with Harvard Medical School. $76,400 2009-2011 (Kieren Mather, Principal Investigator for subcontract) 10% effort

National Institutes of Health. A Novel Marker for Clinical Assessment of Hepatic Glucose Metabolism in Diabetes. (SBIR Phase 1: R43 DK079384) Subcontract with BioChem Analysis Corporation. $45,789. 2008-2009 (Kieren Mather, Principal Investigator for subcontract) 5% effort

The Sandra A. Daugherty Foundation. Relationships of Adiponectin to Vascular and Metabolic Outcomes in the Diabetes Prevention Program. $50,000 2006-2011 (Kieren Mather, Principal Investigator). 5% effort via DPPOS.

National Institutes of Health/National Institute of Diabetes Digestive and Kidney Disease R37 DK42469 Role of Insulin in in vivo Hemodynamics $1,326,320;1999-2004 (Alain Baron, M.D., Principal Investigator) Co-Investigator. 30% effort. For administrative reasons I have been recently assigned as the PI for this project, which was originally awarded to Dr Baron.

Bristol-Myers-Squibb CV138-062. A Multicenter Study to Explore the Mechanism of Action of Glucovance (Gluburide/Metformin HCL), Metformin and Gluburide on Oral Glucose Tolerance as First-Line Therapy in Patients With Type 2 Diabetes. $16,000. 2001-2002 (Kieren Mather, Principal Investigator). 5% effort.

National Institutes of Health, Diabetes Prevention Program, $2,950,100;1997-2001 (David Marrero, Ph.D., Principal Investigator) 5% effort

Clarian Health Values Fund. Metabolic and Virologic Responses to PEG-interferon therapy in Hepatitis C. $80,000. 2003-2004. (Prashant Pandya, Principal Investigator). Co-Investigator, 5% effort.

Sankyo Pharmaceuticals 866-440. Effects of Olmesartan medoxomil, Losartan potassium, and Atenolol on Insulin Sensitivity in Overweight and Obese Subjects with Hypertension. $72,500. 2004-2005.(Kieren Mather, Principal Investigator). 5% effort.

National Institutes of Health. A Novel PET Approach to Measuring Human Myocardial Metabolism. (R21) $410,124. 2005-2008 (Kieren Mather, Principal Investigator). 20% effort

Bristol-Meyers Squibb. A Pilot Study of the Efficacy and Safety of BMS-512148 on Glycemic Control in Subjects with Type 2 Diabetes Treated Aggressively but not Controlled on Combination Antihyperglycemic Therapy with Metformin and/or Thiazolidinedione and Insulin. $32,000, 2007-2008. (Kieren Mather, Principal Investigator). 5% effort.

Eli Lilly and Co. The COMPLETE T2D Trial: Comparison of Insulin Lispro Protamine suspension and detemir in type 2 diabetes mellitus. $64,743, 2007-2008. (Kieren Mather, Principal Investigator). 3% effort.

Merck Inc. A double-blind, placebo-controlled, randomized, parallel clinical trial to study the effect of losartan potassium on endothelial dysfunction and insulin

11rev. Jan 2012

resistance in obese patients with impaired fasting glucose. $49,188, 2007-2009 (Kieren Mather, principal investigator). 5% Effort.

Novo Nordisk, Inc. Liraglutide Effect and Action in Diabetes (LEAD-3): Effect on Glycemic Control of Two Doses of Liraglutide versus Glimepiride in Type 2 Diabetes [A Fifty-Two Week (with Fifty-Two Week Open-label Extension), Double-Blind, Multicenter, Randomized, Parallel Study to Investigate Safety and Efficacy]. $72,000, 2006-2010 (Kieren Mather, Principal Investigator). 5% effort.

American Diabetes Association. Dual Actions of Insulin in the Regulation of Endothelin Activity in vivo in Humans. (Career Development Award) $954,305, 2005-2010 (Kieren Mather, Principal Investigator). 30% effort

Merck, Inc. Medical School Grant. Investigator-initiated award. Treating the Endothelium to Restore Insulin Sensitivity. $100,000 2004-2009. (Kieren Mather, Principal Investigator). 5% effort.

National Institutes of Health. A Non-invasive Surrogate Marker for OGTT to Screen for Pre-diabetes. (SBIR Phase 1) Subcontract with BioChem Analysis Corporation. $47,348. 2008-2009 (Kieren Mather, Principal Investigator for subcontract). 5% effort

PENDING SERVICE GRANTS AND FELLOWSHIPS

SUBMITTED BUT NOT FUNDED SERVICE GRANTS/FELLOWSHIPSTitle Granting Agency Role % Effort Amount Dates

National Institutes of Health. Using GLP-1 to Rebalance Heart Fuel Selection in Diabetes. (R-01) $2,432,534 (Kieren Mather, Principal Investigator). 40% effort. 17th percentile first submission; requires resubmission.

National Institutes of Health. K24 Career Development Award (K-24). $812,202 (Kieren Mather, Principal Investigator). 50% effort. Review date May 16, 2012. 30th percentile score; requires resubmission

Cardiovascular impact of GLP-1 in Type 1 DM. National Institutes of Health. Co-Principal Investigator (with J Tune). 20% effort. $7,692,422. 2011

Characterization of the Variability of Insulin Secretory Parameters in the Meal Tolerance and the Maximal Stimulation Tests of Healthy Subjects. Foundation of the National Institutes of Health. Principal Investigator. 20% effort. $174,923. 2011.

Modulation of human myocardial metabolism by GLP-1. National Institutes of Health. Principal Investigator. 20% effort. $1,368,099. 2010

Augmentation of myocardial insulin action by GLP-1. American Diabetes Association. Principal Investigator. 20% effort. $400,000. 2010

Role of AMPK in metabolic control of myocardial metabolism. American Heart Association. Principal investigator. 5% effort $65000. 2009

(unfunded submitted proposals prior to 2009 omitted)

INVITED PRESENTATIONS – SERVICE LOCALTitle Organization Date

REGIONALTitle Organization Date

12rev. Jan 2012

Diabetes update Methodist Hospital, Merrillville June 2009Emerging diabetes treatments Richmond General Hospital May 2011Diabetes update Methodist Hospital, Merrillville June 2012

NATIONALTitle Organization Date

INTERNATIONALTitle Organization Date

PUBLICATIONS: List all publications in a format consistent with your disciplinary style standards (e.g. APA), listing all authors in the order in which they appear in the publication. Bold your name in citations where multiple authors are listed. All works must be retrievable. Sort publications by the following categories: Teaching, Research/Creative Activity, Service and also by refereed and non-refereed. Separate articles, proceedings papers, books, book chapters, invited reviews, letters to the editor, editorials, book reviews, invited commentaries and abstracts (including professional standards, protocols, software, multimedia presentations, films or videos and other scholarly/creative works designed for electronic technologies). Mark in-rank publications with an asterisk * and those as a mentor with a dagger †. The nature and extent of the your contribution should be presented in the candidate’s statement or in the documentation of teaching, research/creative activity or service and not in the CV. List only works that are published, accepted or “in-press.” Work submitted, under editorial review or in preparation should not be listed but rather may be reported in the candidate’s statement. Candidates for the Three-Year Review and for promotion to Associate Professor should briefly annotate entries to explain the nature and extent of their contribution. If additional explanatory information is needed, include this in an appendix to the dossier.

TEACHINGRefereed

Non-refereed

RESEARCH/CREATIVE ACTIVITYRefereed

Journal Articles 1. Hussain M, Janghorbani M, Schuette S, Considine RV, Chisholm RL, Mather KJ.

Failure of hyperglycemia and hyperinsulinemia to compensate for impaired metabolic response to an oral glucose load. J Diabetes Complications. 2014 Nov 24. pii: S1056-8727(14)00336-5. doi: 10.1016/j.jdiacomp.2014.11.009. [Epub ahead of print] PMID: 25511878.

2. HbA1c as a Predictor of Diabetes and as an Outcome in the Diabetes Prevention Program: A Randomized Clinical Trial. Diabetes Prevention Program Research Group,* prepared by, Knowler WC, Edelstein SL, Goldberg RB, Ackermann RT, Crandall JP, Florez JC, Fowler SE, Herman WH, Horton ES, Kahn SE, Mather KJ, Nathan DM. Diabetes Care. 2014 Oct 21. pii: DC_140886. [Epub ahead of print] PMID: 25336746.

13rev. Jan 2012

3. Thosar SS, Bielko SL, Mather KJ, Johnston JD, Wallace JP. Effect of Prolonged Sitting and Breaks in Sitting Time on Endothelial Function. Med Sci Sports Exerc. 2014 Aug 18. [Epub ahead of print] PMID: 25137367.

4. Goodwill AG, Tune JD, Noblet JN, Conteh AM, Sassoon D, Casalini ED, Mather KJ. Glucagon-like peptide-1 (7-36) but not (9-36) augments cardiac output during myocardial ischemia via a Frank-Starling mechanism. Basic Res Cardiol. 2014 Sep;109(5):426. doi: 10.1007/s00395-014-0426-9. Epub 2014 Jul 9. PMID: 25005062.

5. Mather K. Extrapancreatic effects of GLP-1 and other incretins. Rev Endocr Metab Disord. 2014 Sep;15(3):169. doi: 10.1007/s11154-014-9292-x. Editorial. PMID: 24986555.

6. Perreault L, Temprosa M, Mather KJ, Horton E, Kitabchi A, Larkin M, Montez MG, Thayer D, Orchard TJ, Hamman RF, Goldberg RB; Diabetes Prevention Program Research Group. Regression from prediabetes to normal glucose regulation is associated with reduction in cardiovascular risk: results from the diabetes prevention program outcomes study. Diabetes Care. 2014 Sep;37(9):2622-31. doi: 10.2337/dc14-0656. Epub 2014 Jun 26. PMID: 24969574.

7. Goodwill AG, Mather KJ, Conteh AM, Sassoon DJ, Noblet JN, Tune JD. Cardiovascular and hemodynamic effects of glucagon-like peptide-1. Rev Endocr Metab Disord. 2014 Sep;15(3):209-17. doi: 10.1007/s11154-014-9290-z. PMID: 24881624.

8. Goldberg RB, Temprosa MG, Mather KJ, Orchard TJ, Kitabchi AE, Watson KE; Diabetes Prevention Program Research Group. Lifestyle and Metformin Interventions Have a Durable Effect to Lower CRP and tPA Levels in the Diabetes Prevention Program Except in Those Who Develop Diabetes. Diabetes Care. 2014 Aug;37(8):2253-60. doi: 10.2337/dc13-2471. Epub 2014 May 13. PMID: 24824548.

9. Hannon TS, Kirkman MS, Patel YR, Considine RV, Mather KJ. Profound defects in ß-cell function in screen-detected type 2 diabetes are not improved with glucose-lowering treatment in the early diabetes prevention program (EDIP). Diabetes Metab Res Rev. 2014 May 12. doi: 10.1002/dmrr.2553. [Epub ahead of print] PMID: 24819707.

10. Halban PA, Polonsky KS, Bowden DW, Hawkins MA, Ling C, Mather KJ, Powers AC, Rhodes CJ, Sussel L, Weir GC. β-cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment. J Clin Endocrinol Metab. 2014 Apr 8:jc20141425. [Epub ahead of print] PMID: 24712577.

11. RISE Consortium. Restoring Insulin Secretion (RISE): Design of Studies of β-Cell Preservation in Prediabetes and Early Type 2 Diabetes Across the Life Span. Diabetes Care. 2014 Mar;37(3):780-8. doi: 10.2337/dc13-1879. Epub 2013 Nov 5. PMID:24194506.

12. Walford GA, Ma Y, Christophi CA, Goldberg RB, Jarolim P, Horton E, Mather KJ, Barrett-Connor E, Davis J, Florez JC, Wang TJ; for the Diabetes Prevention Program Research Group. Circulating natriuretic peptide concentrations reflect changes in insulin

14rev. Jan 2012

sensitivity over time in the Diabetes Prevention Program. Diabetologia. 2014 May;57(5):935-9. doi: 10.1007/s00125-014-3183-2. Epub 2014 Feb 20.PMID: 24554005.

13. Mather KJ, Goldberg RB. Clinical use of adiponectin as a marker of metabolic dysregulation. Best Pract Res Clin Endocrinol Metab. 2014 Jan;28(1):107-17. doi: 10.1016/j.beem.2013.06.008. Epub 2013 Jul 22. PMID: 24417950.

14. Florez H, Temprosa MG, Orchard TJ, Mather KJ, Marcovina SM, Barrett-Connor E, Horton E, Saudek C, Pi-Sunyer XF, Ratner RE, Goldberg RB; for the Diabetes Prevention Program Research Group Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes Obes Metab. 2013 Oct 7. doi: 10.1111/dom.12220. [Epub ahead of print] PMID: 24118860.

15. Hussain M, Jangorbhani M, Schuette S, Considine RV, Chisholm RL, Mather KJ. [ 13 C]Glucose Breath Testing Provides a Noninvasive Measure of Insulin Resistance: Calibration Analyses Against Clamp Studies. 2014 Feb;16(2):102-12.. [Epub ahead of print] PMID: 24116833.

16. Goldberg R, Temprosa M, Otvos J, Brunzell J, Marcovina S, Mather K, Arakaki R, Watson K, Horton E, Barrett-Connor E. Lifestyle and metformin treatment favorably influence lipoprotein subfraction distribution in the diabetes prevention program. J Clin Endocrinol Metab. 2013 Oct;98(10):3989-98. doi: 10.1210/jc.2013-1452. Epub 2013 Aug 26. PMID: 23979954.

17. Kim C, Golden SH, Kong S, Nan B, Mather KJ, Barrett-Connor E; Diabetes Prevention Program Research Group. Does hormone therapy affect blood pressure changes in the Diabetes Prevention Program? Menopause. 2013 Aug 12. [Epub ahead of print] PMID: 23942251

18. Patel YR, Kirkman MS, Considine RV, Hannon TS, Mather KJ. Effect of acarbose to delay progression of carotid intima-media thickness in early diabetes. Diabetes Metab Res Rev. 2013 Oct;29(7):582-91. doi: 10.1002/dmrr.2433. PMID: 23908125

19. Nathan DM, Buse JB, Kahn SE, Krause-Steinrauf H, Larkin ME, Staten M, Wexler D, Lachin JM; GRADE Study Research Group. Rationale and design of the glycemia reduction approaches in diabetes : a comparative effectiveness study ( GRADE ). Diabetes Care. 2013 Aug;36(8):2254-61. doi: 10.2337/dc13-0356. Epub 2013 May 20. PMID: 23690531

20. Fisher MM, Perez Chumbiauca CN, Mather KJ, Mirmira RG, Tersey SA. Detection of Islet β Cell Death in vivo by Multiplex PCR Analysis of Differentially Methylated DNA. Endocrinology. 2013 Jul 3. [Epub ahead of print] PMID: 23825129.

21. Kim C, Barrett-Connor E, Randolph JF Jr, Kong S, Nan B, Mather KJ, Golden SH; Diabetes Prevention Program Research Group. Sex steroid levels and response to weight loss interventions among postmenopausal women in the diabetes prevention program. Obesity (Silver Spring). 2013 Jun 26. doi: 10.1002/oby.20527. [Epub ahead of print] PMID: 23804582.

22. Moberly SP, Mather KJ, Berwick ZC, Owen MK, Goodwill AG, Casalini ED, Hutchins GD, Green MA, Ng Y, Considine RV, Perry KM, Chisholm RL, Tune JD. Impaired cardiometabolic responses to glucagon-like peptide 1 in obesity and type 2 diabetes mellitus. Basic Res Cardiol. 2013 Jul;108(4):365. doi: 10.1007/s00395-013-0365-x. Epub 2013 Jun 14. PMID: 23764734.

15rev. Jan 2012

23. Gupta SK, Mi D, Dubé MP, Saha CK, Johnson RM, Stein JH, Clauss MA, Mather KJ, Desta Z, Liu Z. Pentoxifylline, Inflammation, and Endothelial Function in HIV-Infected Persons: A Randomized, Placebo-Controlled Trial. PLoS One. 2013 Apr 9;8(4):e60852. doi: 10.1371/journal.pone.0060852. Print 2013. PMID:23593327.

24. Johnson BD, Mather KJ, Newcomer SC, Mickleborough TD, Wallace JP. Vitamin C prevents the acute decline of flow-mediated dilation after altered shear rate patterns. Appl Physiol Nutr Metab. 2013 Mar;38(3):268-74. doi: 10.1139/apnm-2012-0169. Epub 2012 Nov 21. PMID: 23537017.

25. Mather KJ, Steinberg HO, Baron AD. Insulin resistance in the vasculature. J Clin Invest. 2013 Mar 1;123(3):1003-4. doi: 10.1172/JCI67166. Epub 2013 Mar 1. PMID:23454764

26. Mather KJ. The vascular endothelium in diabetes-a therapeutic target? Rev Endocr Metab Disord. 2013 Mar;14(1):87-99. doi: 10.1007/s11154-013-9237-9.PMID:23397462.

27. Ng Y, Moberly SP, Mather KJ, Brown-Proctor C, Hutchins GD, Green MA. Equivalence of arterial and venous blood for [11C]CO2-metabolite analysis following intravenous administration of 1-[11C]acetate and 1-[11C]palmitate.. Nucl Med Biol. 2013 Jan 7. doi:pii: S0969-8051(12)00308-3. 10.1016/j.nucmedbio.2012.11.011. PMID: 23306135.

28. Kim C, Kong S, Laughlin GA, Golden SH, Mather KJ, Nan B, Randolph JF Jr, Edelstein SL, Labrie F, Buschur E, Barrett-Connor E; for The Diabetes Prevention Program Research Group. Reductions in glucose among postmenopausal women who use and do not use estrogen therapy. Menopause. 2012 Nov 19. PMID: 23168523.

29. Hannon TS, Mather KJ. Measuring the transition to diabetes. J Diabetes Complications. 2012 Nov 16. doi:pii: S1056-8727(12)00282-6. 10.1016/j.jdiacomp.2012.10.002. PMID: 23164632.

30. Florez JC, Jablonski KA, McAteer JB, Franks PW, Mason CC, Mather K, Horton E, Goldberg R, Dabelea D, Kahn SE, Arakaki RF, Shuldiner AR, Knowler WC; Diabetes Prevention Program Research Group. Effects of genetic variants previously associated with fasting glucose and insulin in the diabetes prevention program. PLoS One. 2012;7(9):e44424. PMID: 22984506.

31. Goldberg RB, Mather KJ. Targeting the consequences of the metabolic syndrome in the Diabetes Prevention Program.. Arterioscler Thromb Vasc Biol 2012; 32: 2077. PMID: 22895669.

32. Johnson BD, Mather KJ, Newcomer SC, Mickleborough TD, Wallace JP. Brachial Artery Flow-mediated Dilation Following Exercise with Augmented Oscillatory and Retrograde Shear Rate. Cardiovasc Ultrasound. 2012 Aug 11;10(1):34. PMID: 22883166.

33. Kim C, Golden SH, Mather KJ, Laughlin GA, Kong S, Nan B, Barrett-Connor E, Randolph JF Jr; for The Diabetes Prevention Program Research Group. Racial/Ethnic Differences in Sex Hormone Levels among Postmenopausal Women in the Diabetes Prevention Program. J Clin Endocrinol Metab. 2012 Aug 14; PMID:22879633.

34. Orchard TJ, Temprosa M, Barrett-Connor E, Fowler S, Goldberg R, Mather K, Marcovina S, Montez M, Ratner R, Saudek C, Sherif H, Watson K; The Diabetes Prevention Program Outcomes Study Research Group; prepared on behalf of the DPPOS Research Group. Long-term effects of the Diabetes Prevention Program interventions on cardiovascular risk factors: a report from the DPP Outcomes Study. Diabet Med. 2012 Jul 19. doi: 10.1111/j.1464-5491.2012.03750.x. [Epub ahead of print] PMID: 22812594.

16rev. Jan 2012

35. Florez JC, Jablonski KA, Taylor A, Mather K, Horton E, White NH, Barrett-Connor E, Knowler WC, Shuldiner AR, Pollin TI; for the Diabetes Prevention Program Research Group. The C Allele of ATM rs11212617 Does Not Associate With Metformin Response in the Diabetes Prevention Program. Diabetes Care. 2012 Jun 29. PMID: 22751958.

36. Kim C, Kong S, Laughlin GA, Golden SH, Mather KJ, Nan B, Edelstein SL, Randolph JF Jr, Labrie F, Buschur E, Barrett-Connor E. Endogenous sex hormone changes in postmenopausal women in the diabetes prevention program. J Clin Endocrinol Metab. 2012 Aug;97(8):2853-61. Epub 2012 Jun 11. PMID: 22689695.

37. *Perreault L, Pan Q, Mather KJ, Watson K, Hamman RF, Kahn SE for the Diabetes Prevention Program Research Group. Regression From Pre-Diabetes to Normal Glucose Regulation is Associated with Long-term Reduction in Diabetes Risk: Results from the Diabetes Prevention Program Outcomes Study. The Lancet 2012;9379:2243. PMID: 22683134.

38. Kim C, Kong S, Laughlin GA, Golden SH, Mather KJ, Nana B, Edelstein SL, Randolph JF, Labrie F, Buschur E, Barrett-Connor E. Endogenous sex hormone changes in postmenopausal women in the Diabetes Prevention Program. J Clin Endocrinol Metab 2012 97(8) 2853. Published ahead of print June 11, 2012. PMID: 22689695.

39. *Mather KJ, Cristophi CA, Jablonski KA, Knowler WC, Goldberg RB, Kahn SE, Spector T, Dastani Z, Waterworth D, Richards B, Funahashi T, Pi-Sunyer FX, Pollin TI, Florez JC and Franks PW, for the Diabetes Prevention Program Research Group. Common variants in genes encoding adiponectin (ADIPOQ) and its receptors (ADIPOR1/2), adiponectin concentrations, and diabetes incidence in the Diabetes Prevention Program. Diabet Med. 2012 Mar 24. doi: 10.1111/j.1464-5491.2012.03662.x. [Epub ahead of print] PMID: 22443353.

40. *†Moberly SP, Berwick ZC, Kohr M, Svendsen M, Mather KJ, Tune JD. Intracoronary glucagon-like peptide 1 preferentially augments glucose uptake in ischemic myocardium independent of changes in coronary flow. Exp Biol Med (Maywood). 2012 Mar 1;237(3):334-42. Epub 2012 Feb 16. PMID:22345302.

41. *†Lteif A, Chisholm R, Gilbert K, Considine RV, Mather KJ. Effects of losartan on whole body, skeletal muscle and vascular insulin responses in obesity/insulin resistance without hypertension. Diabetes Obes Metab. 2012 Mar;14(3):254-61. Epub 2011 Nov 24. PMID:22051059.

42. *Gupta SK, Shen C, Mather KJ, Agarwal R, Dubé MP Neither Proteinuria Nor Albuminuria Is Associated With Endothelial Dysfunction in HIV-Infected Patients Without Diabetes or Hypertension. J Infect Dis. 2011 Oct 19 204(12):1946-50. doi: 10.1093/infdis/jir668. Epub 2011 Oct 19. . PMID: 22013226.

43. *†Johnson BD, Mather KJ, Wallace JP. Mechanotransduction of shear in the endothelium: Basic studies and clinical implications. Vasc Med. 2011 Oct;16(5):365-77. PMID: 22003002.

44. *Perlstein TS, Henry RR, Mather KJ, Rickels MR, Abate NI, Grundy SM, Mai Y, Albu JB, Marks JB, Pool JL, Creager MA. Effect of angiotensin receptor blockade on insulin sensitivity and endothelial function in abdominally obese hypertensive patients with impaired fasting glucose. Clin Sci (Lond). 2011 Aug 24. [Epub ahead of print] PMID: 21861845.

17rev. Jan 2012

45. *Majithia AR, Jablonski KA, McAteer JB, Mather KJ, Goldberg RB, Kahn SE, Florez JC; for the DPP Research Group.Association of the SLC30A8 missense polymorphism R325W with proinsulin levels at baseline and after lifestyle, metformin or troglitazone intervention in the Diabetes Prevention Program. Diabetologia. 2011 Oct;54(10):2570-4. Epub 2011 Jul 21. PMID: 21779873.

46. *†Patel YR, Han KA, Lteif AA, Wallace JP, Mather KJ. A cross-sectional evaluation of seasonality as a determinant of endothelial function. Nitric Oxide. 2011 Oct 30;25(3):282-7. Epub 2011 Jul 3. PMID: 21757021.

47. *†Gorgey AS, Mather KJ, Cupp HR, Gater DR. Effects of Resistance Training on Adiposity and Metabolism after Spinal Cord Injury. Med Sci Sports Exerc. 2011 Jun 8. PMID: 21659900.

48. *†Gorgey AS, Mather KJ, Poarch HJ, Gater DR. Influence of motor complete spinal cord injury on visceral and subcutaneous adipose tissue measured by multi-axial magnetic resonance imaging. J Spinal Cord Med. 2011 Jan;34(1):99-109. PMID: 21528633.

49. *†Han KA, Patel Y, Lteif AA, Chisholm R, Mather KJ. Contributions of dysglycaemia, obesity, and insulin resistance to impaired endothelium-dependent vasodilation in humans. Diabetes Metab Res Rev. 2011 May;27(4):354-61. doi: 10.1002/dmrr.1183. PMID: 21309061.

50. *†Singal P, Janghorbani M, Schuette SA, Chisholm R, Mather KJ. Intra-individual variability of CO ₂ breath isotope enrichment compared to blood glucose in the oral glucose tolerance test. Diabetes Technol Ther. 2010 Dec;12(12):947-53. PMID: 21128841.

51. *†Gorgey AS, Mather KJ, Gater DR. Central adiposity associations to carbohydrate and lipid metabolism in individuals with complete motor spinal cord injury. Metabolism. 2011 Jun;60(6):843-51. Epub 2010 Sep 25. PMID: 20870252.

52. *Dubé MP, Shen C, Mather KJ, Waltz J, Greenwald M, Gupta SK. Relationship of body composition, metabolic status, antiretroviral use, and HIV disease factors to endothelial dysfunction in HIV-infected subjects. AIDS Res Hum Retroviruses. 2010 Aug;26(8):847-54. PMID: 20673142.

53. *Gupta SK, Johnson RM, Mather KJ, Clauss M, Rehman J, Saha C, Desta Z, Dubé MP Anti-inflammatory treatment with pentoxifylline improves HIV-related endothelial dysfunction: a pilot study. AIDS. 2010 Jun 1;24(9):1377-80. PMID: 20559042

54. *†Wallace JP, Johnson B, Padilla J, Mather KJ Postprandial lipaemia, oxidative stress and endothelial function: a review. Int J Clin Pract 2010 64:389. PMID: 20456177

55. *Mather KJ, Lteif AA, Veeneman E, Fain R, Giger S, Perry K, Hutchins GD. Role of Endogenous ET-1 in the Regulation of Myocardial Blood Flow in Lean and Obese Humans. Obesity (Silver Spring). 2010 Jan;18(1):63-70. Epub 2009 Jun 18. PMID: 19543207

56. *Singal P, Muniyappa R, Chisholm R, Hall G, Chen H, Quon MJ, Mather KJ. Simple Modeling Allows Prediction of Steady-State Glucose Disposal Rate from Early Data in Hyperinsulinemic Glucose Clamps. Am J Physiol Endocrinol Metab. 2010 298 E229. PMID: 19920219

57. *The Diabetes Prevention Program Research Group, Goldberg RB, Temprosa M, Haffner S, Orchard TJ, Ratner RE, Fowler SE, Mather K, Marcovina S, Saudek C, Matulik MJ, Price D. The Effect of Progression from Impaired Glucose Tolerance to Diabetes on

18rev. Jan 2012

Cardiovascular Risk Factors and its Amelioration by Lifestyle and Metformin Intervention: The Diabetes Prevention Program Randomized Trial. Diabetes Care 2009 Apr;32(4):726-32. PMID: 19171717

58. *†Padilla J, Johnson BD, Newcomer SC, Wilhite DP, Mickleborough TD, Fly AD, Mather KJ, Wallace JP. Adjusting Flow-Mediated Dilation for Shear Stress Stimulus Allows Demonstration of Endothelial Dysfunction in a Population with Moderate Cardiovascular Risk. J Vasc Res. 2009 Jun 30;46(6):592-600. PMID: 19571579

59. *Mather K. Surrogate measures of insulin resistance: of rats, mice, and men. Am J Physiol 2009 296 E398-9. PMID: 19171846.

60. *†Lteif AA, Fulford AD, Considine RV, Gelfand I, Baron AD, Mather KJ. Hyperinsulinemia fails to augment ET-1 action in the skeletal muscle vascular bed in vivo in humans. Am J Physiol 2008 295 E1510-7 (Epub 2008 Oct 28). PMID: 18957616

61. *Title LM, Lonn E, Charbonneau F, Fung M, Mather KJ, Verma S, Anderson TJ. Relationship between brachial artery flow-mediated dilatation, hyperemic shear stress, and the metabolic syndrome.Vasc Med 2008 13 263. PMID: 18940902.

62. *Dube MP, Shen C, Greenwald M, Mather KJ. No impairment of endothelial function nor insulin sensitivity with 4 weeks of the HIV protease inhibitors atazanavir or lopinavir-ritonavir in healthy subjects without HIV infection: A placebo-controlled trial. Clin Inf Dis 2008; 47:567. PMID:18636958.

63. *†Yoon N, Lteif AA, Han KA, Mather KJ. Endothelin contributes differently to peripheral vascular tone and blood pressure in human obesity and diabetes. J Am Soc Hypertension 2008; 2:182. PMID: 20409901.

64. *†Padilla J, Johnson B, Newcomer S, Wilhite DP, Mickleborough TD, Flye AD, Mather KJ, Wallace JP. Normalization of flow-mediated dilation to shear stress area under the curve eliminates the impact of variable hyperemic stimulus. Cardiovascular Ultrasound 2008, 6:44. PMID: 18771594.

65. *Mather KJ, Funahashi T, Edelstein S, Bray G, Kahn S, Crandall J, Marcovina S, Goldstein B, Goldberg R for the Diabetes Prevention Program. Adiponectin, Change in Adiponectin, and Progression to Diabetes in the Diabetes Prevention Program. Diabetes 2008, 57;980. PMID: 18192541.

66. *Gupta SK, Johnson RM, Saha C, Mather KJ, Greenwald ML, Waltz JS, Rehman J, Dubé MP. Improvement in HIV-Related Endothelial Dysfunction Using the Anti-Inflammatory Agent Salsalate: A Pilot Study. J AIDS 2008,22;653. PMID: 18317009.

67. *Gupta SK, Mather KJ, Agarwal R, Saha CK, Considine RV, Dubé MP. Proteinuria and endothelial dysfunction in stable HIV-infected patients: A pilot study. J Acquir Immune Defic Syndr 2007, 45;596. PMID:17704684.

68. †Han K, Lteif AA, Mather KJ. Blood Pressure Response to ETA Antagonism in Human Obesity and Diabetes Mellitus. J Human Hypertension, 2006;20:798[epub 2006 Jul 20]. PMID: 16855627.

69. †Lteif AA, Vaishnava P, Baron AD, Mather KJ. Endothelin limits insulin action in obese/insulin-resistant humans. Diabetes 2007;56:728. PMID: 17327443.

70. †Strawbridge AB, Elmendorf JS, Mather KJ. Interactions of Endothelin and Insulin: Expanding Parameters of Insulin Resistance. Curr Diab Rev 2006;2:317. PMID: 18220636.

19rev. Jan 2012

71. Mather K, Verma S. Function determines structure in the vasculature: lessons from insulin resistance. Am J Physiol Regul Integr Comp Physiol. 2005 Aug;289(2):R305-R306. PMID: 16014446.

72. Haffner S, Temprosa M, Crandall J, Fowler S, Goldberg R, Horton E, Marcovina S, Mather K, Orchard T, Ratner R, Barrett-Connor E; Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes 2005 ;54:1566-72. PMID: 15855347.

73. Lteif AA, Han KA and Mather KJ. Obesity, Insulin Resistance and the Metabolic Syndrome: Determinants of Endothelial Dysfunction Differ Between Caucasians and African Americans. Circulation 2005;112:32. PMID: 15983246.

74. †Brame L, Considine RV, Yamauchi M, Baron AD, Mather KJ. Insulin and endothelin in the acute regulation of adiponectin in vivo in humans. Obesity Research 2005;13:582. PMID: 15833944.

75. †Lteif AA and Mather KJ. Insulin Resistance, Metabolic Syndrome and Vascular Diseases: Update on Mechanistic Linkages. Canadian Journal of Cardiology 2004; 20(SupplB):66B-76B. PMID: 15309208.

76. †Mather KJ, Lteif AA, Steinberg HO, Baron AD. Interactions Between Endothelin and Nitric Oxide in the Regulation of Vascular Tone in Obesity and Diabetes Mellitus. Diabetes 2004; 53:2060-6. PMID: 15277386.

77. Mather KJ. Noninvasive Detection of Vascular Dysfunction in Diabetes (Invited Editorial). Diabetes Care. 2004 Mar;27(3):831-3.

78. †Brame L, Verma S, Anderson TJ, and Mather KJ. Insulin Resistance As A Therapeutic Target For Improved Endothelial Function: Metformin. Curr Drug Targets Cardiovasc Haematol Disord. 2004 Mar;4(1):53-63. PMID: 15032652.

79. Mather KJ, Steinberg HO, and Baron AD. Weight Loss and Endothelial Function in Obesity (Editorial). Diabetes Care 2003; 26(6):1927-8. PMID: 12766136.

80. †Lteif AA, Mather KJ, Clark CM. Diabetes and Heart Disease: An Evidence Driven Guide to Risk Factors Management in Diabetes. Cardiol Rev 2003; 11(5):262-74. PMID: 12943604.

81. Mather KJ, Mirzamohammadi B, Steinberg HO, and Baron AD. Endothelin contributes to basal vascular tone and endothelial dysfunction in human obesity and type 2 diabetes mellitus. Diabetes 2002;51(12):3517-23. PMID: 12453909.

82. Mather KJ, Paradisi GP, Leaming R, Hook G, Steinberg HO, Fineberg N, Hanley R, and Baron AD. Role of amylin in insulin secretion and action in humans – antagonist studies across the spectrum of insulin sensitivity. Diabetes Metab Res Rev. 2002 Mar-Apr;18(2):118-26. PMID: 11994903.

83. Mather KJ, Hunt AE, Steinberg HO, Paradisi G, Quon MJ, Katz A, Hook G, and Baron AD. Repeatability Characteristics of Simple Indices of Insulin Resistance – Implications for Research Applications. J Clin Endocrinol Metab 2001;86:5457-5464. PMID: 11701722.

84. Mather KJ, Anderson TJ and Verma S. Insulin action in the vasculature: physiology and pathophysiology. J Vasc Res 2001, 38(5):415-22. PMID: 11561143.

85. Mather KJ, Verma S, Anderson TJ. Improved endothelial function with metformin in diet-treated type 2 diabetes mellitus. J Am Coll Cardiol 2001;37:1344-1350. PMID: 11300445.

20rev. Jan 2012

86. Verma S, Lovren F, Dumont A, Mather K, Maitland A, Kieser T, Triggle C, Anderson TJ. Endothelin receptor blockade improves endothelial function in human internal mammary arteries. Cardiovascular Research 2001;49:146-151. PMID: 11121806.

87. Verma S, Raj SR, Shewchuk L, Mather KJ, Anderson TJ. Cyclooxygenase-2 blockade does not impair endothelial function in healthy volunteers: Randomized evaluation of Rofecoxib versus Naproxen on endothelium-dependent vasodilation. Circulation 2001;104:2879-2882. PMID: 11739299.

88. Mather KJ. Endothelial Function in the Polycystic Ovary Syndrome. 1st Virtual Congress of Endocrinology, Brazil. January 2001. http://www.endocrinologia.org.br

89. Verma S, Lovren F, Dumont A, Mather K, Maitland A, Kieser T, Triggle C, Anderson TJ. Tetrahydrobiopterin improves endothelial function in human saphenous veins: A novel mechanism. J Thorac Cardiovasc Surg 2000;120:668-71. PMID: 11003746.

90. Mather KJ, Norman EG, Prior JC, and Elliott TG. Progesterone improves endothelium-dependent vasodilation in healthy postmenopausal women. J Clin Endocrinol Metab 2000; 85: 4644-4649. PMID: 11134122.

91. Mather KJ, Meddings JB, Beck PL, Scott RBS, Hanley DA. Prevalence of IgA-Antiendomysial Antibody in Asymptomatic Low Bone Mineral Density. Am J Gastroenterol 2001;96:120-125. PMID: 11197240.

92. Mather KJ, Laakso M, Edelman SV, Hook G and Baron AD. Evidence for physiologic coupling of limb blood flow and insulin mediated glucose metabolism. Am J Physiol (Endocrinol Metab) 2000: 279 :E1264-1270. PMID: 11093913.

93. Katz A, Nambi SS, Mather K, Baron AD, Follman DA, Sullivan G and Quon MJ. Quantitative insulin-sensitivity check index (QUICKI): A simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000;85:2402-2410. PMID: 10902785.

94. Mather KJ, Verma S, Corenblum B, and Anderson TJ. Normal Endothelial Function Despite Insulin Resistance in Healthy Women with the Polycystic Ovary Syndrome. J Clin Endocrinol Metab 2000; 85:1851-1856. PMID: 10843164.

95. Mather KJ, Kwan F and Corenblum B. Hyperinsulinemia in Polycystic Ovary Syndrome Correlates with Increased Cardiovascular Risk Independent of Obesity. Fert Ster 2000;73:150-6. PMID: 10632431.

96. Mather KJ, Chik CL and Corenblum B. Maintenance of Serum Calcium by Parathyroid Hormone-Related Peptide During Lactation in a Hypoparathyroid Patient. J Clin Endocrinol Metab 1999;84:424-427. PMID: 10022395.

97. Mather KJ, Corenblum B and Edwards, A. Amiodarone therapy: Thyroid side effects. Perspectives in Cardiology 1998;4(6/7):27-35.

98. Verma S, Mather K, Dumont AS, Anderson TJ. Pharmacologic modulation of insulin resistance and hyperinsulinemia in polycystic ovary syndrome: The emerging role. The Endocrinologist 1998;8:418-424.

99. Burgess E, Mather K, Ross S and Josefsberg Z. Office Hypertension in Non Insulin Dependent Diabetics. Diabetologia 1991;34(9):684. PMID: 1955103.

100. French RJ, Doyle DD, Anscomb L, Lee MC, Mather KJ, and Guo Y. Kinetic Properties Distinguish Batrachotoxin-Activated Cardiac Sodium Channels from Other Subtypes in Planar Lipid Bilayers. Biophys J 1990;57:297a.

21rev. Jan 2012

Journal Articles (in press)

Journal Articles (Submitted)1. Patel Y, Kirkman MS, Considine RV, Hannon TS, Mather KJ. Determinants of

Progression of Early Diabetes. Diabetologia, in review2.

Journal Articles (In preparation)1. Moberly S, DeGrado TP, Hutchins GD Mather KJ,. Metabolic flexibility in human

diabetic myocardium after metabolic correction. 2. Mather KJ, Fulford AD, Considine RV. Insulin fails to modulate endogenous ET-1

production or action under NOS blockade in skeletal muscle in humans.3. Mather KJ, Fulford AD, Chisholm R, Considine RV. Exogenous nitrate replacement

suppresses endogenous ET-1 action in skeletal muscle in obese humans4. Mather KJ, Chisholm R, Fulford AD, Daniel AD, Considine RV. Free fatty acids induce

inflammation but do not augment endogenous ET-1 activity in human skeletal muscle.

Journal Articles from Collaborative ProjectsThis list includes published manuscripts from projects in which I have made contributions to the design, conduct or performance of the study but have not necessarily been directly involved in producing the published manuscript. Manuscripts which are directly attributable to me are also listed above under “Journal Articles”

Diabetes Prevention Program: Through my participation as a site investigator in the DPP and on oversight and study management committees I have contributed to the scientific output of the DPP and DPPOS (Outcome Study), which includes:

1. Edelstein SL, Knowler WC, Bain RP, Andres R, Barrett-Connor EL, Dowse GK, Haffner SM, Pettit DJ, Sorkin JD, Muller DC, Collins VR, Hamman RF. Predictors of progression from impaired glucose tolerance to NIDDM: An analysis of six prospective studies. Diabetes. 1997 Apr; 46(4): 701-710. PMCID: PMC2517225

2. The Diabetes Prevention Program Research Group. The Diabetes Prevention Program: Design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care. 1999 Apr; 22(4): 623-634. PMCID: PMC1351026

3. *The Diabetes Prevention Program Research Group. Response to Adler, Turner, Singer et al. Diabetes Care. 1999 Oct; 22(10): 1757-1758. PMID: 10526759

4. Fujimoto WY. Background and recruitment data for the U.S. Diabetes Prevention Program. Diabetes Care. 2000 Apr; 23 Suppl 2: B11-3. PMCID: PMC2505054

22rev. Jan 2012

5. The Diabetes Prevention Program Research Group. The Diabetes Prevention Program: Baseline characteristics of the randomized cohort. Diabetes Care. 2000 Nov; 23(11): 1619-1629. PMCID: PMC1360735

6. The Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002 Feb 7; 346(6): 393-403. PMCID: PMC1370926

7. The Diabetes Prevention Program Research Group. The Diabetes Prevention Program: Recruitment methods and results. Control Clin Trials. 2002 Apr; 23(2): 157-171. PMCID: PMC2556984

8. †Knowler W for the Diabetes Prevention Program Research Group. Response to Bo-abbas, Brousseau, Louria, Benjamin et al. N Engl J Med. 2002 Jun 6; 346(23):1829-1830

9. Wylie-Rosette J, Delahanty L. An integral role of the dietitian: Implications of the Diabetes Prevention Program. J Am Diet Assoc. 2002 Aug; 102(8):1065-1068. PMCID: PMC2562572

10. Delahanty LM, Meigs JB, Hayden D, Williamson DA, Nathan DM, and the DPP Research Group. Psychological and behavioral correlates of baseline BMI in the Diabetes Prevention Program (DPP). Diabetes Care. 2002 Nov; 25(11):1992-1998. PMCID: PMC1475806

11. The Diabetes Prevention Program Research Group. Hypertension, insulin, and proinsulin in participants with impaired glucose tolerance. Hypertension. 2002 Nov; 40(5): 679-686. PMCID: PMC2516377

12. The Diabetes Prevention Program Research Group. The Diabetes Prevention Program (DPP): Description of lifestyle intervention. Diabetes Care. 2002 Dec; 25(12): 2165-5171. PMCID: PMC1282458

13. The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care. 2003 Jan; 26(1): 36-47. PMCID: PMC1402339

14. The Diabetes Prevention Program Research Group. Effects of withdrawal from metformin on the development of diabetes in the Diabetes Prevention Program. Diabetes Care. 2003 Apr; 26(4): 977-980. PMCID: PMC1360737

15. Molitch M, Fujimoto W, Hamman R, Knowler W for the Diabetes Prevention Program Research Group. The Diabetes Prevention Program and its global implications (Singapore paper). J Am Soc Nephrol. 2003 Jul; 14(7 Suppl 2): S103-107

23rev. Jan 2012

16. The Diabetes Prevention Program Research Group. Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care. 2003 Sep; 26(9): 2518-2523. PMCID: PMC1360736

17. The Diabetes Prevention Program Research Group. Achieving weight and activity goals among Diabetes Prevention Program lifestyle participants. Obes Res. 2004 Sep; 12(9): 1426-1434. PMCID: PMC2505058

18. Mayer-Davis EJ, Sparks KC, Hirst K, Costacou T, Lovejoy JC, Regensteiner JG, Hoskin M, Kriska AM, Bray G and the Diabetes Prevention Program Research Group. Dietary intake in the Diabetes Prevention Program cohort: Baseline and 1-year post-randomization. Ann Epidemiol. 2004 Nov; 14(10): 763-772. PMCID: PMC2505047

19. The Diabetes Prevention Program Research Group. Strategies to identify adults at high risk for type 2 diabetes. Diabetes Care. 2005 Jan; 28(1): 138-144. PMCID: PMC1314971

20. Herman WH, Hoerger TJ, Brandle M, Hicks K, Sorensen S, Zhang P, Hamman RF, Ackermann RT, Engelgau MM, Ratner RE for the Diabetes Prevention Program Research Group. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med. 2005 Mar; 142(5): 323-32. PMCID: PMC2701392

21. The Diabetes Prevention Program Research Group. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes. 2005 Apr; 54(4): 1150-1156. PMCID: PMC1351025

22. The Diabetes Prevention Program Research Group. Depression symptoms and antidepressant medicine use in Diabetes Prevention Program participants. Diabetes Care. 2005 Apr; 28(4): 830-837. PMCID: PMC1314970

23. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care. 2005 Apr; 28(4): 888-894. PMCID: PMC1307521

24. Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, Fowler S, for the Diabetes Prevention Program Research Group. The effect of metformin and lifestyle intervention on the metabolic syndrome: The Diabetes Prevention Program Randomized Trial. Ann Intern Med. 2005 Apr 19; 142(8): 611-619. PMCID: PMC2505046

25. Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes. 2005 May; 54(5): 1566-1572. PMCID: PMC1314967

26. The Diabetes Prevention Program Research Group. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the Diabetes Prevention Program: Effects

24rev. Jan 2012

of lifestyle intervention and metformin. Diabetes. 2005 Aug; 54(8): 2404-2414. PMCID: PMC1360738

27. The Diabetes Prevention Program Research Group. Lipid, lipoproteins, C-reactive protein, and hemostatic factors at baseline in the Diabetes Prevention Program. Diabetes Care. 2005 Oct; 28(10): 2472-2479. PMCID: PMC1404506

28. Hoskin M, Begay S, Bolin P, Hermes J, Ingraham L, Killean T, Nelson J, Percy C, Scurlock N, Shovestull LE, Tomchee C, the Diabetes Prevention Program and Action for Health in Diabetes (Look AHEAD) research groups. Providing lifestyle interventions in American Indian communities. Obesity Management Journal 2005 Dec; 1(6): 251-255.

29. Brown JS, Wing R, Barrett-Connor E, Nyberg LM, Kusek JW, Orchard TJ, Ma Y, Vittinghoff E, Kanaya AM for the Diabetes Prevention Program Research Group. Lifestyle intervention is associated with lower prevalence of urinary incontinence: The Diabetes Prevention Program. Diabetes Care. 2006 Feb; 29(2): 385-390.

30. Ratner R for the Diabetes Prevention Program Research Group. An Update on the Diabetes Prevention Program. Endocr Prac. 2006 Jan-Feb; 12 Suppl 1: 20-24. PMCID: PMC1751934

31. Carnethon MR, Prineas RJ, Temprosa M, Zhang Z, Uwaifo G, Molitch ME for the Diabetes Prevention Program Research Group. The association among autonomic nervous system function, incident diabetes, and intervention arm in the Diabetes Prevention Program. Diabetes Care. 2006 Apr; 29(4): 914-919. PMCID: PMC1751934

32. Delahanty LM, Conroy MB, Nathan DM, and the Diabetes Prevention Program Research Group. Psychological predictors of physical activity in the Diabetes Prevention Program. J Am Diet Assoc. 2006 May; 106(5): 698-705. PMCID: PMC2495077

33. Kriska AM, Edelstein SL, Hamman RF, Otto A, Bray GA, Mayer-Davis EJ, Wing RR, Horton ES, Haffner SM, Regensteiner JG. Physical activity in individuals at risk for diabetes: Diabetes Prevention Program. Med Sci Sports Exerc. 2006 May; 38(5): 826-832. PMCID: PMC1570396

34. Florez JC, Jablonski KA, Bayley N, Pollin TI, de Bakker PIW, Shuldiner AR, Knowler WC, Nathan DM and Altshuler D for the Diabetes Prevention Program Research Group. TCF7L2 Polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med. 2006 Jul 20; 355(3): 241-250. PMCID: PMC1762036

35. Hamman RF, Wing RR, Edelstein SL, Lachin JM, Bray GA, Delahanty L, Hoskin M, Kriska AM, Mayer-Davis EJ, Pi-Sunyer X, Regensteiner J, Venditti B, Wylie-Rosett J, for the Diabetes Prevention Program Research Group. Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care. 2006 Sep; 29(9): 2102-2107. PMCID: PMC1762038

25rev. Jan 2012

36. Walker EA, Molitch M, Kramer MK, Kahn S, Ma Y, Edelstein S, Smith K, Johnson MK, Kitabchi A, Crandall J, for the Diabetes Prevention Program Research Group. Adherence to preventive medications: Predictors and outcomes in the Diabetes Prevention Program. Diabetes Care. 2006 Sept; 29(9): 1997-2002. PMCID: PMC1762037

37. The Diabetes Prevention Program Research Group. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. J Gerontol A Biol Sci Med Sci. 2006 Oct; 61(10): 1075-1081. PMCID: PMC1783677

38. The Diabetes Prevention Program Research Group. Relationship of body size and shape to the development of diabetes in the Diabetes Prevention Program. Obesity. 2006 Nov; 14(11): 2107-2117. PMCID: PMC2373982

39. Florez JC, Jablonski KA, Sun MW, Bayley N, Kahn SE, Shamoon H, Hamman RF, Knowler WC, Nathan DM and Altshuler D for the Diabetes Prevention Program Research Group. Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone. J Clin Endocrinol Metab. 2007; 92(4):doi:10.1210/jc.2006-2275. PMCID: PMC2267936

40. The Diabetes Prevention Program Research Group. The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program. Diabet Med. 2007 Feb; 24(2): 137-144. PMCID: PMC2267935

41. Florez JC, Jablonski KA, Kahn SE, Franks PW, Dabelea D, Hamman RF, Knowler WC, Nathan CM and Altshuler D for the Diabetes Prevention Program Research Group. Type 2 diabetes-associated missense polymorphisms KCNJ11 E23K and ABCC8 A1369S influence progression to diabetes and response to interventions in the Diabetes Prevention Program. Diabetes. 2007 Feb; 56(2): 531-536. PMCID: PMC2267937

42. Lachin JM, Christophi CA, Edelstein SL, Ehrmann DA, Hamman RF, Kahn SE, Knowler WC, Nathan DM for the Diabetes Prevention Program Research Group. Factors associated with diabetes onset during metformin versus placebo therapy in the Diabetes Prevention Program. Diabetes. 2007 Apr; 56(4): 1153-1159. PMCID: PMC2533728

43. The Diabetes Prevention Program Research Group. Body size and shape changes and the risk of diabetes in the Diabetes Prevention Program (DPP). Diabetes. 2007 Jun; 56(6): 1680-1685. PMCID: PMC2528279

44. Hoerger TJ, Hicks KA, Sorenson SW, Herman WH, Ratner RE, Ackermann RT, Zhang P, Englegau MM. The cost-effectiveness of screening for prediabetes among overweight U.S. adults. Diabetes Care. 2007 Nov; 30(11): 2874-2879. PMID: 17698614

45. Herman WH, Ma Y, Uwaifo G, Haffner S, Kahn SE, Horton ES, Lachin JM, Montez MG, Brenneman T, Barrett-Connor E for the Diabetes Prevention Program Research Group. Differences in A1C by race and ethnicity among patients with impaired glucose

26rev. Jan 2012

tolerance in the Diabetes Prevention Program. Diabetes Care. 2007 Oct; 30(10): 2453-2457. PMCID: PMC2373980

46. Franks PW, Jablonski KA, Delahanty L, Hanson RL, Kahn SE, Altshuler D, Knowler WC, Florez JC for the Diabetes Prevention Program Research Group. The Pro12Ala variant at the peroxisome proliferator-activated receptor gamma gene and change in obesity-related traits in the Diabetes Prevention Program. Diabetologia. 2007 Dec; 50(12): 2451-2460. PMCID: PMC2453532

47. Florez JC, Jablonski KA, McAteer J, Sandhu MS, Wareham NJ, Barroso I, Franks PW, Altshuler D, Knowler WC for the Diabetes Prevention Program. Testing of diabetes-associated WFS1 polymorphisms in the Diabetes Prevention Program. Diabetologia. 2008 Mar; 51(3): 451-457. PMCID: PMC2483955

48. Mather K, Funahashi T, Matsuzawa Y, Edelstein S, Bray G, Kahn S, Crandall J, Marcovina S, Goldstein B, Goldberg R for the DPP Research Group. Adiponectin, change in adiponectin, and progression to diabetes in the Diabetes Prevention Program. Diabetes. 2008 Apr; 57(4): 980-986. PMCID: PMC2529455

49. Rubin RR, Ma Y, Marrero DG, Peyrot M, Barrett-Connor EL, Kahn SE, Haffner SM, Price DW, Knowler WC for the Diabetes Prevention Program Research Group. Elevated depression symptoms, antidepressant medicine use and risk of developing diabetes during the Diabetes Prevention Program. Diabetes Care. 2008 Mar; 31(3): 420-426. PMCID: PMC2373986

50. Bray GA, Jablonski KA, Fujimoto WF, Barrett-Connor E, Haffner S, Hanson RL, Hill JO, Hubbard V, Kriska A, Stamm E, Pi-Sunyer FX for the Diabetes Prevention Program Research Group. Relation of central adiposity and body mass index to the development of diabetes in the Diabetes Prevention Program. Am J Clin Nutr. 2008 May; 87(5): 1212-1218. PMCID: PMC2517222

51. Crandall JP, Knowler WC, Kahn SE, Marrero D, Florez JC, Bray GA, Haffner SM, Hoskin M, Nathan DM for the Diabetes Prevention Program Research Group. The prevention of type 2 diabetes. Nat Clin Pract Endocrinol Metab. 2008 Jul; 4(7): 382-393. PMCID: PMC2573045

52. Moore AF, Jablonski KA, McAteer JB, Saxena R, Pollin TI, Hanson RL, Shuldiner AR, Knowler WC, Altshuler D, Florez JC for the Diabetes Prevention Program Research Group. Extension of type 2 diabetes genome-wide association scan results in the Diabetes Prevention Program. Diabetes. 2008 Sept; 57(9): 2503-2510. PMID: 18544707

53. Perreault L, Ma Y, Dagogo-Jack S, Horton E, Marrero D, Crandall J, Barrett-Connor E for the Diabetes Prevention Program Research Group. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care. 2008 July; 31(7): 1416-1421. PMCID: PMC2453677

27rev. Jan 2012

54. Venditti EM, Bray GA, Carrion-Petersen ML, Delahanty LM, Edelstein SM, Hamman RF, Hoskin MA, Knowler WC, Ma Y for the Diabetes Prevention Program Research Group. First versus repeat treatment with a lifestyle intervention program: attendance and weight loss outcomes. Int J Obes. 2008 Oct; 32(10): 1537-1544. PMCID: PMC2574826

55. Friedman AN, Marrero D, Ma Y, Ackermann R, Narayan V, Barrett-Connor E, Watson K, Knowler WC, Horton ES for the Diabetes Prevention Program Research Group. Value of urinary albumin creatinine ratio as a predictor of type 2 diabetes in pre-diabetic individuals. Diabetes Care. 2008 Dec; 31(12): 2344-2348. PMCID: PMC2584193

56. Ratner RE, Christophi CA, Metzger BE, Dabelea D, Bennett PH, Pi-Sunyer X, Fowler S, Kahn SE; The Diabetes Prevention Program Research Group. Prevention of Diabetes in Women with a History of Gestational Diabetes: Effects of Metformin and Lifestyle Interventions. J Clin Endocrinol Metab. 2008 Dec; 93(12): 4774-4779. PMCID: PMC2626441

57. Franks PW, Jablonski KA, Delahanty LM, McAteer JB, Kahn SE, Knowler WC, Florez JC and Diabetes Prevention Program Research Group. Assessing gene-treatment interactions at the FTO and INSIG2 loci on obesity-related traits in the Diabetes Prevention Program. Diabetologia. 2008 Dec; 51(12): 2214-2223. PMID: 18839134

58. Moore AF, Jablonski KA, Mason CC, McAteer JB, Arakaki RF, Goldstein BJ, Kahn SE, Kitabchi AE, Hanson RL, Knowler WC, Florez JC for The Diabetes Prevention Program Research Group. The associate of ENPP1 K121Q with diabetes incidence is abolished by lifestyle modification in the Diabetes Prevention Program. J Clin Endocrinol Metab. 2009 Feb; 94(2): 449-455. PMCID: PMC2646511

59. Ma Y, Temprosa M, Fowler S, Prineas R, Montez M, Brown-Friday J, Carrion-Petersen M, and Whittington T for the Diabetes Prevention Program Research Group. Evaluating the accuracy of an aneroid sphygmomanometer in a clinical trial setting. Am J Hypertens. 2009 Mar; 22(3): 263-266. PMCID: PMC2699679

60. Goldberg RB, Temprosa M, Haffner S, Orchard TJ, Ratner RE, Fowler SE, Mather K, Marcovina S, Saudek C, Matulik MJ, Price D, Diabetes Prevention Program Research Group. Effect of progression from impaired glucose tolerance to diabetes on cardiovascular risk factors and its amelioration by lifestyle and metformin intervention: the Diabetes Prevention Program randomized trial by the Diabetes Prevention Program Research Group. Diabetes Care 2009 Apr; 32(4): 726-732. PMCID: PMC2660486

61. The Diabetes Prevention Program Research Group. Changes in albumin excretion in the Diabetes Prevention Program. Diabetes Care. 2009 Apr; 32(4): 720-725. PMCID: PMC2660489

62. Ackermann RT, Edelstein SL, Venkat Narayan KM, Zhang P, Engelgau MM, Herman WH, Marrero DG, Diabetes Prevention Program Research Group. Changes in Health

28rev. Jan 2012

State Utilities with Changes in Body Mass in the Diabetes Prevention Program. Obesity (Silver Spring) 2009 Dec; 17(12): 2176-2181. PMCID: PMC3135001

63. Perreault L, Kahn SE, Christophi CA, Knowler WC, Hamman RF, Diabetes Prevention Program Research Group. Regression from pre-diabetes to normal glucose regulation in the diabetes prevention program. Diabetes Care 2009 Sep; 32(9): 1583-1588. PMCID: PMC2732165

64. Crandall JP, Polsky S, Howard AA, Perreault L, Bray GA, Barrett-Connor E, Brown-Friday J, Whittington T, Foo S, Ma Y, Edelstein SL, Diabetes Prevention Program Research Group. Alcohol consumption and diabetes risk in the Diabetes Prevention Program. Am.J.Clin.Nutr. 2009 Sep; 90(3): 595-601. PMCID: PMC2728644

65. Diabetes Prevention Program Research G. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009 Nov 14; 374(9702): 1677-1686. PMCID: PMC3135022

66. Krakoff J, Clark JM, Crandall JP, Wilson C, Molitch ME, Brancati FL, Edelstein SL, Knowler WC, Diabetes Prevention Program Research Group. Effects of Metformin and Weight Loss on Serum Alanine Aminotransferase Activity in the Diabetes Prevention Program. Obesity (Silver Spring) 2010 Sept; 18(9): 1762-1767. PMCID: PMC3135003

67. Jablonski KA, McAteer JB, de Bakker PI, Franks PW, Pollin TI, Hanson RL, Saxena R, Fowler S, Shuldiner AR, Knowler WC, Altshuler D, Florez JC, Diabetes Prevention Program Research Group. Common Variants in 40 Genes Assessed for Diabetes Incidence and Response to Metformin and Lifestyle Intervention in the Diabetes Prevention Program. Diabetes 2010 Oct; 59(10): 2672-2681. PMCID: PMC3279522

68. Rubin RR, Ma Y, Peyrot M, Marrero DG, Price DW, Barrett-Connor E, Knowler WC, Diabetes Prevention Program Research Group. Antidepressant Medicine Use and Risk of Developing Diabetes during the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study. Diabetes Care. 2010 Dec; 33(12): 2549-2551. PMCID: PMC2992187

69. Hivert MF, Jablonski KA, Perreault L, Saxena R, McAteer JB, Franks PW, Hamman RF, Kahn SE, Haffner S, DIAGRAM Consortium, Meigs JB, Altshuler D, Knowler WC, Florez JC, Diabetes Prevention Program Research Group. Updated genetic score based on 34 confirmed type 2 diabetes loci is associated with diabetes incidence and regression to normoglycemia in the diabetes prevention program. Diabetes [Internet]. 2011 Apr; 60(4): 1340-1348. PMCID: PMC3064108

70. Pollin TI, Jablonski KA, McAteer JB, Saxena R, Kathiresan S, Kahn SE, Goldberg RB, Altshuler D, Florez JC, for the Diabetes Prevention Program Research Group. Triglyceride response to an intensive lifestyle intervention is enhanced in carriers of the GCKR Pro446Leu polymorphism. J Clin Endocrinol Metab. 2011 Jul; 96(7): E1142-1147. PMCID: PMC3205512

29rev. Jan 2012

71. Kim C, Edelstein SL, Crandall JP, Dabelea D, Kitabchi AE, Hamman RF, Montez MG, Perreault L, Foulkes MA, Barrett-Connor E, for the Diabetes Prevention Program Research Group. Menopause and risk of diabetes in the diabetes prevention program. Menopause. 2011 Aug; 18(8): 857-868. PMCID: PMC3500880

72. Majithia AR, Jablonski KA, McAteer JB, Mather KJ, Goldberg RB, Kahn SE, Florez JC, for the DPP Research Group. Association of the SLC30A8 missense polymorphism R325W with proinsulin levels at baseline and after lifestyle, metformin or troglitazone intervention in the diabetes prevention program. Diabetologia. 2011 Oct; 54(10): 2570-2574. PMCID: PMC3444290

73. McCaffery JM, Jablonski KA, Franks PW, Dagogo-Jack S, Wing RR, Knowler WC, Delahanty L, Dabelea D, Hamman R, Shuldiner AR, Florez JC, for the Diabetes Prevention Program,Research Group. TCF7L2 polymorphism, weight loss and proinsulin:Insulin ratio in the diabetes prevention program. PLoS ONE. 2011; 6(7): e21518. PMCID: PMC3144193

74. Florez H, Ma Y, Crandall JP, Perreault L, Marcovina SM, Bray GA, Saudek CD, Barrett-Connor E, Knowler WC, for the Diabetes Prevention Program Research Group. Parental longevity and diabetes risk in the diabetes prevention program. J Gerontol A Biol Sci Med Sci. 2011 Nov; 66(11): 1211-1217. PMCID: PMC3193521

75. Kilpelainen TO, Qi L, Brage S, Sharp SJ, Sonestedt E, Demerath E, Ahmad T, Mora S, Kaakinen M, Sandholt CH, Holzapfel C, Autenrieth CS, Hypponen E, Cauchi S, He M, Kutalik Z, Kumari M, Stancakova A, Meidtner K, Balkau B, Tan JT, Mangino M, Timpson NJ, Song Y, Zillikens MC, Jablonski KA, Garcia ME, Johansson S, Bragg-Gresham JL, Wu Y, van Vliet-Ostaptchouk JV, Onland-Moret NC, Zimmermann E, Rivera NV, Tanaka T, Stringham HM, Silbernagel G, Kanoni S, Feitosa MF, Snitker S, Ruiz JR, Metter J, Larrad MT, Atalay M, Hakanen M, Amin N, Cavalcanti-Proenca C, Grontved A, Hallmans G, Jansson JO, Kuusisto J, Kahonen M, Lutsey PL, Nolan JJ, Palla L, Pedersen O, Perusse L, Renstrom F, Scott RA, Shungin D, Sovio U, Tammelin TH, Ronnemaa T, Lakka TA, Uusitupa M, Rios MS, Ferrucci L, Bouchard C, Meirhaeghe A, Fu M, Walker M, Borecki IB, Dedoussis GV, Fritsche A, Ohlsson C, Boehnke M, Bandinelli S, van Duijn CM, Ebrahim S, Lawlor DA, Gudnason V, Harris TB, Sorensen TI, Mohlke KL, Hofman A, Uitterlinden AG, Tuomilehto J, Lehtimaki T, Raitakari O, Isomaa B, Njolstad PR, Florez JC, Liu S, Ness A, Spector TD, Tai ES, Froguel P, Boeing H, Laakso M, Marmot M, Bergmann S, Power C, Khaw KT, Chasman D, Ridker P, Hansen T, Monda KL, Illig T, Jarvelin MR, Wareham NJ, Hu FB, Groop LC, Orho-Melander M, Ekelund U, Franks PW, Loos RJ. Physical activity attenuates the influence of FTO variants on obesity risk: A meta-analysis of 218,166 adults and 19,268 children. PLoS Med. 2011 Nov; 8(11): e1001116. PMCID: PMC3206047

76. Delahanty LM, Pan Q, Jablonski KA, Watson KE, McCaffery JM, Shuldiner A, Kahn SE, Knowler WC, Florez JC, Franks PW, Diabetes Prevention Program Research Group. Genetic predictors of weight loss and weight regain after intensive lifestyle

30rev. Jan 2012

modification, metformin treatment, or standard care in the Diabetes Prevention Program. Diabetes Care. 2012;35(2):363-366.   [Published] PMCID: PMC3263869

77. Perreault L, Pan Q, Mather KJ, Watson KE, Hamman RF, Kahn SE, Diabetes Prevention Program Research Group. Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet. 2012;379(9833):2243-2251.   [Published] PMCID:PMC3555407

78. Pollin TI, Isakova T, Jablonski KA, de Bakker PI, Taylor A, McAteer J, Pan Q, Horton ES, Delahanty LM, Altshuler D, Shuldiner AR, Goldberg RB, Florez JC, Franks PW, Diabetes Prevention Program Research Group. Genetic Modulation of Lipid Profiles following Lifestyle Modification or Metformin Treatment: The Diabetes Prevention Program. PLoS Genet. 2012;8(8):e1002895.  [Published] PMCID:PMC3431328

79. Florez JC, Jablonski KA, McAteer JB, Franks PW, Mason CC, Mather K, Horton E, Goldberg R, Dabelea D, Kahn SE, Arakaki RF, Shuldiner AR, Knowler WC, Diabetes Prevention Program Research Group. Effects of genetic variants previously associated with fasting glucose and insulin in the Diabetes Prevention Program. PLoS One. 2012;7(9):e44424.  [Electronic version; Published] PMCID:PMC3439414

80. Goldberg RB, Mather K. Targeting the consequences of the metabolic syndrome in the Diabetes Prevention Program. Arterioscler Thromb Vasc Biol. 2012;32(9):2077-2090.  [Published] PMCID:PMC3901161

81. Price DW, Ma Y, Rubin RR, Perreault L, Bray GA, Marrero D, Knowler WC, Barrett-Connor E, Lacoursiere DY, for the Diabetes Prevention Program Research Group. Depression as a Predictor of Weight Regain Among Successful Weight Losers in the Diabetes Prevention Program. Diabetes Care. 2013;36(2):216-221.   [Epub ahead of print; Published] PMCID:PMC3554307

82. Christophi CA, Resnick HE, Ratner RE, Temprosa M, Fowler S, Knowler WC, Shamoon H, Barrett-Connor E. Confirming Glycemic Status in the Diabetes Prevention Program: Implications for Diagnosing Diabetes in High Risk Adults. J Diabetes Complications. 2012;27(2):150-7.  PMCID:PMC3594066

83. Mather KJ, Christophi CA, Jablonski KA, Knowler WC, Goldberg RB, Kahn SE, Spector T, Dastani Z, Waterworth D, Richards JB, Funahashi T, Pi-Sunyer FX, Pollin TI, Florez JC, Franks PW, for the Diabetes Prevention Program Research Group (2012). Common variants in genes encoding adiponectin (ADIPOQ) and its receptors (ADIPOR1/2), adiponectin concentrations, and diabetes incidence in the Diabetes Prevention Program. Diabet.Med. 2012 Dec;29(12):1579-88. doi: 10.1111/j.1464-5491.2012.03662.x. (Epub). PMID: 22443353.

84. Florez H, Pan Q, Ackermann RT, Marrero DG, Barrett-Connor E, Delahanty L, Kriska A, Saudek CD, Goldberg RB, Rubin RR, for the Diabetes Prevention Program Research Group. Impact of Lifestyle Intervention and Metformin on Health-Related Quality of Life: the Diabetes Prevention Program Randomized Trial. J Gen Intern Med. 2012;27(12):1594-1601.   [Published] PMCID:PMC3509296

85. Orchard TJ, Temprosa M, Barrett-Connor E, Fowler S, Goldberg R, Mather K, Marcovina S, Montez M, Ratner R, Saudek C, Sherif H, Watson K, The Diabetes Prevention Program Outcomes Study Research Group. Long term effects of the Diabetes Prevention Program’s interventions on cardiovascular risk factors: a report from the DPP Outcomes Study. Diabet Med. 2013;30(1):46-55.   [Published] PMCID:PMC3524372

31rev. Jan 2012

86. Herman WH, Edelstein SL, Ratner RE, Montez MG, Ackermann RT, Orchard TJ, Foulkes MA, Zhang P, Saudek CD, Brown MB. Effectiveness and Cost-Effectiveness of Diabetes Prevention Among Adherent Participants. Am J Manag Care. 2013;19(3):194-202.  PMCID:PMC3985133

87. Marrero D, Pan Q, Barrett-Connor E, de Groot M, Zhang P, Percy C, Florez H, Ackermann R, Montez M, Rubin RR, DPPOS Research Group. Impact of diagnosis of diabetes on health related quality of life among high risk individuals: The Diabetes Prevention Program Outcomes Study. Qual Life Res. 2013;23(1):75-88.   [Epub ahead of print] doi: 10.1007/s11136-013-0436-3. PMCID:PMC3890371

88. Ezzat S, Zheng L, Florez JC, Stefan N, Mayr T, Hliang MM, Jablonski K, Harden M, Stancakova A, Laakso M, Haring HU, Ullrich A, Asa SL. The cancer-associated FGFR4-G388R polymorphism enhances pancreatic insulin secretion and modifies the risk of diabetes. Cell Metab. 2013;17(6):929-940.   [Epub ahead of print] doi: 10.1016/j.cmet.2013.05.002; 10.1016/j.cmet.2013.05.002. PMCID:PMC4005358

89. Maruthur NM, Ma Y, Delahanty LM, Nelson JA, Aroda V, White NH, Marrero D, Brancati FL, Clark JM, for the Diabetes Prevention Program Research Group. Early Response to Preventive Strategies in the Diabetes Prevention Program. J Gen Intern Med. 2013;28(12):1629-36.  PMCID:PMC3832727

90. Goldberg RB, Temprosa M, Otvos J, Brunzell J, Marcovina SM, Mather KJ, Arakaki RF, Watson KE, Horton ES, Barrett-Connor E. Lifestyle and metformin treatment favorably influence lipoprotein sub-fraction distribution in the Diabetes Prevention Program. JCEM. 2013;98(10):3989-98.  PMCID:PMC3790618

91. Pan Q, Delahanty LM, Jablonski KA, Knowler WC, Kahn SE, Florez JC, Franks PW, Diabetes Prevention Program Research Group. Variation at the melanocortin 4 receptor gene and response to weight-loss interventions in the Diabetes Prevention Program. Obesity (Silver Spring). 2013;21(9):E520-6.  PMCID:PMC4023472

92. Florez H, Temprosa MG, Orchard TJ, Mather KJ, Marcovina SM, Barrett-Connor E, Horton E, Saudek C, Pi-Sunyer XF, Ratner RE, Goldberg RB. Metabolic Syndrome Components and Their Response to Lifestyle and Metformin Interventions are Associated with Differences in Diabetes Risk in Persons with Impaired Glucose Tolerance. Diabetes Obes Metab. 2013;16(4):326-33.  PMCID:PMC3943638

93. Davis NJ, Ma Y, Delahanty LM, Hoffman HJ, Mayer-Davis E, Franks PW, Brown-Friday J, Isonaga M, Kriska AM, Venditti EM, Wylie-Rosett J, Diabetes Prevention Program Research Group. Predictors of sustained reduction in energy and fat intake in the Diabetes Prevention Program Outcomes Study intensive lifestyle intervention. J Acad Nutr Diet. 2013;113(11):1455-1464.  PMCID:PMC3962017

94. Sullivan SD, Jablonski KA, Florez JC, Dabelea D, Franks PW, Dagogo-Jack S, Kim C, Knowler WC, Christophi CA, Ratner R, for the Diabetes Prevention Program Research Group. Genetic Risk of Progression to Type 2 Diabetes and Response to Intensive Lifestyle or Metformin in Prediabetic Women With and Without a History of Gestational Diabetes. Diabetes Care. 2014;37(4):909-911.  PMCID:PMC3964494

95. Franks PaulW, Christophi CostasA, Jablonski KathleenA, Billings LianaK, Delahanty LindaM, Horton EdwardS, Knowler WilliamC, Florez JoseC. Common variation at PPARGC1A/B and change in body composition and metabolic traits following preventive interventions: the Diabetes Prevention

32rev. Jan 2012

Program. Diabetologia. 2014;57(3):485-490.   [Epub ahead of print] doi: 10.1007/s00125-013-3133-4. PMCID:PMC4154629

96. Billings LK, Jablonski KA, Ackerman RJ, Taylor A, Fanelli RR, McAteer JB, Guiducci C, Delahanty LM, Dabelea D, Kahn SE, Franks PW, Hanson RL, Maruthur NM, Shuldiner A, Mayer-Davis EJ, Knowler WC, Florez JC, for the Diabetes Prevention Program Research Group Rockville MD. The Influence of rare Genetic variation in SLC30A8 on diabetes incidence and beta-cell function. J Clin Endocrinol Metab. 2014;99(5):E926-30.  PMCID:PMC4010688

97. Venditti Elizabeth, Wylie-Rosett Judith, Delahanty Linda, Mele Lisa, Hoskin Mary, Edelstein Sharon, for the Diabetes Prevention Program Research Group. Short and long-term lifestyle coaching approaches used to address diverse participant barriers to weight loss and physical activity adherence. Int J Behav Nutr Phys Act. 2014;11(1):16 PMCID:PMC4015875

98. Walford GA, Ma Y, Christophi CA, Goldberg RB, Jarolim P, Horton E, Mather KJ, Barrett-Connor E, Davis J, Florez JC, Wang TJ, for the Diabetes Prevention Program Research Group. Circulating natriuretic peptide concentrations reflect changes in insulin sensitivity over time in the Diabetes Prevention Program. Diabetologia. 2014;57(5):935-939.  PMCID:PMC4158711

99. Dabelea D, Ma Y, Knowler WC, Marcovina S, Saudek CD, Arakaki R, White NH, Kahn SE, Orchard TJ, Goldberg R, Palmer J, Hamman RF, The Diabetes Prevention Program Research Group. Diabetes autoantibodies do not predict progression to diabetes in adults: the Diabetes Prevention Program. Diabetic Med. 2014;31(9):1064-8.  PMCID:PMC4138247

100. Perreault Leigh, Temprosa Marinella, Mather Kieren J, Horton Ed, Kitabchi Abbas, Larkin Mary, Montez Maria G, Thayer Debra, Orchard Trevor J, Hamman Richard F, Goldberg Ronald B, for the Diabetes Prevention Program Research Group. Regression From Prediabetes to Normal Glucose Regulation Is Associated With Reduction in Cardiovascular Risk: Results From the Diabetes Prevention Program Outcomes Study. Diabetes Care. 2014;37(9):2622-31.  PMCID:PMC4140157

101. Delahanty LM, Pan Q, Jablonski KA, Aroda VR, Watson KE, Bray GA, Kahn SE, Florez JC, Perreault L, Franks PW, for the Diabetes Prevention Program Research Group. Effects of Weight Loss, Weight Cycling, and Weight Loss Maintenance on Diabetes Incidence and Change in Cardiometabolic Traits in the Diabetes Prevention Program. Diabetes Care. 2014;37(10):2738-45.  PMCID:PMC4170126

102. Goldberg R, Temprosa M, Mather K, Orchard T, Kitabchi A, Watson K. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the Diabetes Prevention Program except in those who develop diabetes. Diabetes Care. 2014;37(8):2253-60.  PMCID:PMC4113172

103. Vimaleswaran KS, Cavadino A, Berry DJ, LifeLines Cohort Study investigators, Jorde R, Dieffenbach AK, Lu C, Alves AC, Heerspink HJ, Tikkanen E, Eriksson J, Wong A, Mangino M, Jablonski KA, Nolte IM, Houston DK, Ahluwalia TS, van der Most PJ, Pasko D, Zgaga L, Thiering E, Vitart V, Fraser RM, Huffman JE, de Boer RA, Schottker B, Saum KU, McCarthy MI, Dupuis J, Herzig KH, Sebert S, Pouta A, Laitinen J, Kleber ME, Navis G, Lorentzon M, Jameson K, Arden N, Cooper JA, Acharya J, Hardy R, Raitakari O, Ripatti S, Billings LK, Lahti J, Osmond C, Penninx BW, Rejnmark L, Lohman KK, Paternoster L, Stolk RP, Hernandez DG, Byberg

33rev. Jan 2012

L, Hagstrom E, Melhus H, Ingelsson E, Mellstrom D, Ljunggren O, Tzoulaki I, McLachlan S, Theodoratou E, Tiesler CM, Jula A, Navarro P, Wright AF, Polasek O, International Consortium for Blood Pressure (ICBP), Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium, Global Blood Pressure Genetics (Global BPGen) consortium, Caroline Hayward, Wilson JF, Rudan I, Salomaa V, Heinrich J, Campbell H, Price JF, Karlsson M, Lind L, Michaelsson K, Bandinelli S, Frayling TM, Hartman CA, Sorensen TI, Kritchevsky SB, Langdahl BL, Eriksson JG, Florez JC, Spector TD, Lehtimaki T, Kuh D, Humphries SE, Cooper C, Ohlsson C, Marz W, de Borst MH, Kumari M, Kivimaki M, Wang TJ, Power C, Brenner H, Grimnes G, van der Harst P, Snieder H, Hingorani AD, Pilz S, Whittaker JC, Jarvelin MR, Hypponen E. Association of vitamin D status with arterial blood pressure and hypertension risk: a mendelian randomisation study. Lancet Diabetes Endocrinol. 2014;2(9):719-729.

104. Hoskin MaryA, Bray GeorgeA, Hattaway Kathy, Khare-Ranade PrajaktaA, Pomeroy Jeremy, Semler LindaN, Weinzierl ValarieA, Wylie-Rosett Judith. Prevention of Diabetes Through Lifestyle Intervention: Lessons Learned from the Diabetes Prevention Program and Outcomes Study and its Translation to Practice. Curr Nutr Rep. 2014:1-15.  PMCID:PMC4221569

105. The Diabetes Prevention Program (DPP) Research Group, Hamman RF, Horton E, Barrett-Connor E, Bray GA, Christophi C, Crandall J, Florez JC, Fowler S, Goldberg R, Kahn SE, Knowler WC, Lachin J, Murphy MB, Venditti E. Factors Affecting the Decline in Incidence of Diabetes in the Diabetes Prevention Program Outcome Study (DPPOS). Diabetes. 2014.  [Epub ahead of print] doi: DB_140333 [pii]. PMCID:PMC - Journal in Process

106. Diabetes Prevention Program Research Group. HbA1c as a Predictor of Diabetes and as an Outcome in the Diabetes Prevention Program: A Randomized Clinical Trial. Diabetes Care. 2014 PMCID:PMC Journal - In Process

107. Phelan S, Kanaya AM, Ma Y, Vittinghoff E, Barrett-Connor E, Wing R, Kusek JW, Orchard TJ, Crandall JP, Montez MG, Brown JS, Diabetes Prevention Program Research Group. Long-term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. Int J Urol. 2014.  [Epub ahead of print] doi: 10.1111/iju.12654 [doi]. PMCID:PMC Journal - In Process

108. Jaacks LM, Ma Y, Davis N, Delahanty LM, Mayer-Davis EJ, Franks PW, Brown-Friday J, Isonaga M, Kriska AM, Venditti EM, Wylie-Rosett J, The Diabetes Prevention Program Research Group. Long-term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Med. 2014;31(12):1631-42.  PMCID:PMC Journal - In Process

TINSAL-T2D109. Goldfine AB, Fonseca V, Jablonski KA, Chen YD, Tipton L, Staten MA, Shoelson SE;

Targeting Inflammation Using Salsalate in Type 2 Diabetes Study Team. Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial. Ann Intern Med. 2013 Jul 2;159(1):1-12. doi: 10.7326/0003-4819-159-1-201307020-00003. PMID: 23817699.

34rev. Jan 2012

110. Goldfine AB, Buck JS, Desouza C, Fonseca V, Chen YD, Shoelson SE, Jablonski KA, Creager MA; TINSAL-FMD (Targeting Inflammation Using Salsalate in Type 2 Diabetes–Flow-Mediated Dilation) Ancillary Study Team. Targeting inflammation using salsalate in patients with type 2 diabetes: effects on flow-mediated dilation (TINSAL-FMD). Diabetes Care. 2013 Dec;36(12):4132-9. doi: 10.2337/dc13-0859. Epub 2013 Oct 15. PMID: 24130358.

Abstracts1. Johnson BD, Mather KJ, Newcomer SC, Mickleborough TD, Wallace JP. Vitamin C

prevents attenuation of flow-mediation dilation following exercise with augmented oscillatory and retrograde shear. American College of Sports Medicine, 2012.

2. Patel YR, Kirkman MS, Considine RV, Hannon TS, Mather KJ. Effects of progression on anthropometric and metabolic variables on Intima-Media Thickness in the Early Diabetes Intervention Project (EDIP) study population. American College of Cardiology 2012.

3. Patel YR, Kirkman MS, Considine RV, Hannon TS, Steinberger DS, Mather KJ. Vascular predictors for progression of fasting glucose during 5 years in the Early Diabetes Intervention Project (EDIP) Study Population. American College of Physicians, Michigan Meeting 2012.

4. Moberly SP, Berwick ZC, Kohr MC, Svendsen M, Hutchins GD, Mather KJ, Tune JD. Impaired myocardial response to glucagon-like peptide 1 in humans with Type 2 diabetes mellitus. American Society of Clinical Investigation 2012, A125.

5. Moberly SP, Berwick ZC, Kohr MC, Svendsen M, Mather KJ, Tune JD. Intracoronary glucagon-like peptide 1 preferentially augments glucose uptake in ischemic myocardium independent of changes in coronary flow. Experimental Biology 2012.

6. Chawla AR, Spencer SM, Alloosh M, Byrd JP, McKenney ML, Schultz KA, Mather KJ, Sturek M. Ossabaw miniature swine models with mutant vs. non-mutant AMP kinase alleles for study of electrocardiographic properties during myocardial ischemia. Experimental Biology 2012.

7. Ng Y, Moberly SP, Mather KJ, Hutchins GD, Green MA. Equivalence of arterial and venous blood for 11CO2-metabolite analysis following intravenous administration of 11C-acetate and 11C-palmitate. Society of Nuclear Medicine 2012.

8. Wang Z, DiMeglio L, Mather KJ, Thurmond DE Anti-Apoptotic. Effects of Dietary Supplements in Pancreatic Islet β-cells. Indiana University CTSI Research Day 2012.

9. Patel YA, Kirkman MS, Considine RV, Hannon T, Mather KJ. "Impact of Acarbose on carotid Intima - Media Thickness and Its Progression during 5 years in the Early Diabetes Intervention Project (EDIP) Study Population". American Medical Association 2011. First place poster award to Dr Patel.

10. Gilbert K, Lteif A, Chisholm R, Considine R, Mather KJ. Effects of losartan on whole-body, skeletal muscle, and vascular insulin responses. American Diabetes Association 2010 #P845

11. Mather KJ, Chisholm R, Potts J, Cornner D, Considine RV. Interactions of insulin and free fatty acids on endothelin action in vivo in humans. American Diabetes Association 2009 #A691.

35rev. Jan 2012

12. Mather KJ, Chisholm R, Potts J, Cornner D, Considine RV. Interactions of nitric oxide and insulin on endothelin action in vivo in humans. American Diabetes Association 2009 #A690.

13. Padilla, J., B.D. Johnson, S.C. Newcomer, D.P. Wilhite, T.D. Mickleborough, A.D. Fly, K.J. Mather, & J.P. Wallace. Adjusting flow-mediated dilation for shear stress allows detection of endothelial dysfunction in a moderate-risk population. Medicine and Science in Sports & Exercise, 41(5), (S)253, 2009.

14. Gupta SK, Chen S, Chandan C, Mather KJ, Waltz, J, Greenwald M, Dube MP. Associations between endothelial dysfunction and proteinuria, albuminuria, and renal function in stable, HIV-infected patients. 16th conference on retroviruses and opportunistic infections 2009. Oral presentation O-125.

15. Mather KJ, Chisholm R, Cornner D, Perry K, Hutchins GD, DeGrado T. Evidence for normal metabolic flexibility in human diabetic myocardium. American Diabetes Association 2008 Poster presentation

16. Considine RV, Fulford A, Chisholm R, Mather KJ. Does L-NMMA unmask endothelium-mediated insulin induced vasoconstriction in humans? American Diabetes Association 2008 Poster presentation.

17. Singal P, Muinyappa R, Chisholm R Hall G, Quon MJ, Mather KJ. Minimizing glucose clamp procedure time by modeling the glucose infusion rate. American Diabetes Association 2008..

18. Gupta SK, Johnson RM, Mather KJ, Greenwald, ML, Chandan SK, Dube MP. The Anti-Inflammatory Agent Salsalate Improves HIV-Related Endothelial Dysfunction: A Pilot Study. 9th International Workshop on Adverse Drug Reaction sand Lipodystrophy in HIV. 2007. Poster 10C954

19. Dube MP, Shen C, Greenwald M, Mather KJ. Effects of 4 weeks of atazanavir, lopinavir/ritonavir, or placebo on endothelial function and insulin sensitivity in healthy men. 9th International Workshop on Adverse Drug Reaction sand Lipodystrophy in HIV. 2007. Poster presentation.

20. Mather KJ, Lteif AA, Fain R, Hutchins GD. Role of endogenous ET-1 in the regulation of myocardial blood flow in lean and obese humans. American Diabetes Association 2007 #0060-OR

21. Mather KJ, Funahashi T, Edelstein S, Bray G, Kahn S, Crandall J, Marcovina S, Goldstein BJ, Goldberg R for the Diabetes Prevention Program. Adiponectin and Change in Adiponectin Predict Diabetes Outcomes in the Diabetes Prevention Program. American Diabetes Association 2007 #1304-P

22. Han KA, Lteif AA, Mather KJ. Glycemia versus Insulin Resistance in the Determination of Endothelial Dysfunction. American Diabetes Association 2005, #749-P

23. Lteif AA, Han KA, Mather KJ. Obesity, Insulin Resistance, and the Metabolic Syndrome: Determinants of Endothelial Function in Caucasians and African Americans. American Diabetes Association 2005, #747-P

24. Lteif AA, Vaishanava P, Baron AD, Mather KJ. Endogenous Endothelin Activity Limits Skeletal Muscle and Whole Body Insulin Action in Obese Humans. American Diabetes Association 2005, #1589-P

25. Brame L, Considine RV, Yamauchi M, Baron AD, Mather KJ. Insulin’s Ability To Suppress Adiponectin in vivo in Humans Is Independent of Endothelin Activity. American Diabetes Association 2004 #402-P.

36rev. Jan 2012

26. Lteif AA, Baron AD, Mather KJ. Hemodynamic and Endothelial Effects of Endothelin Antagonism in Lean and Obese Humans. American Diabetes Association 2004 #370-PD.

27. Brame L, Considine RV, Yamauchi M, Mather KJ. Insulin’s Ability To Suppress Adiponectin In Vivo in Humans Is Independent of Endothelin. Central Society for Clinical Research/American Federation for Medical Research, Chicago April 2004.

28. Mather KJ, Hutchins GD, Lteif AA, Baron AD. Endothelin Contributes to the Regulation of Cardiac Blood Flow in Humans. American Heart Association 2003 #16800

29. Lteif AA, Steinberg HO, Baron AD, Mather KJ. Waist Circumference Encompasses Metabolic Syndrome Effects on Endothelial Function. American Heart Association 2003 #16195.

30. Yan R, Anderson TH, Mather KJ, Verma S, Charbonneau F, BuithieuJ, Title L, Changers C, Lonn E. Obesity Predicts Atherogenic Metabolic Abnormalities and Atherosclerosis. American Heart Association 2003 #8749

31. Mather KJ, Steinberg HO, Lteif AA, Baron AD. Endothelin Antagonism Does Not Alter Metabolic Response to Insulin in Humans. American Diabetes Association 2003 #1431. Diabetes 2003; 52 Suppl 1:A331.

32. Lteif AA, Steinberg HO, Mather KJ. Endothelin antagonism, but not vasodilation per se, improves endothelial function in obesity. American Diabetes Association 2003 #2061. Diabetes 2003; 52 Suppl 1:A476

33. . Pandya PK, Alba L, Taylor R, Smith OJ, Mather KJ. Impaired glucose homeostasis in hepatitis C patients without cirrhosis. American Association for the Study of Liver Diseases 2001, abstract #100620

34. Mather KJ, Steinberg HO, Mirzamohammadi B and Baron AD. Endothelin Blockade During Hyperinsulinemic Clamps Corrects Endothelial Dysfunction in Insulin Resistant Obese Humans. American Diabetes Association, June 2002, Oral Presentation

35. Lteif A, Mirzamohammadi B, Steinberg HO, Baron AD and Mather KJ. Poor Correlation of Circulating ET-1 Concentrations With Effects of Endothelin Receptor Blockade in Lean, Obese and Type 2 Diabetic Subjects. American Diabetes Association June 2002, Poster Presentation.

36. Lteif A, Steinberg HO, Mather KJ. Phentolamine Induces Vasodilation But Fails to Improve Endothelial Function. Indiana University Department of Medicine Resident Research Competition 2002.

37. Dwivedi R, Gaddis NP, Mather KJ, Scierczynski PA, Bourdillon PD. 43-year-old female with thyrotoxic angina and normal coronary angiogram. American Association of Clinical Endocrinology May 2002. Endocr Pract 2002; 8(no.2); 143-4.

38. Verma S, Edworthy S, Charbonneau F, Mather KJ, Lonn E and Anderson TJ for the FATE investigators. ENOS polymorphisms and Subclinical Atherosclerosis. Canadian Cardiovascular Society 2002, Edmonton AB.

39. Mather KJ, Lonn E, Verma S, Edworthy S, Fung M, Charbonneau F and Anderson TJ for the FATE investigators. Insulin Resistance, the Metabolic Syndrome and Carotid Intima-Medial Thickness. Canadian Cardiovascular Society 2002, Edmonton AB.

40. Shankar S, Mather KJ, Pete A, Steinberg HO. Insulin Sensitivity Determined by the Homeostasis Model Correlates with Endothelium Dependent Vasodilation. American Diabetes Association 2001, Abstract #672.

41. Mather KJ, Hyndman E, Verma S, Jones C, Parsons H, Edworthy S, Bridge P and Anderson TJ. Homozygosity for the T786C Variant of eNOS Predisposes to Insulin

37rev. Jan 2012

Resistance in Healthy Caucasian Males. American Diabetes Association 2001, President’s Poster Session.

42. Mather KJ, Mirzamohammadi B, Steinberg HO, and Baron AD. Insulin stimulates greater endothelin tone in obese than in lean humans. American Heart Association 2001, Abstract #114975.

43. Mather KJ, Steinberg HO, Mirzamohammadi B, Baron AD. Endothelin Blockade Augments Vascular Nitric Oxide in Insulin Resistance/Diabetes. American Diabetes Association 2001, Abstract #163.

44. Mather KJ, Steinberg HO, Mirzamohammadi B, Hook G, Baron AD. ET-1A Receptor Blockade Improves Endothelium-Dependent Vasodilation in Insulin Resistant Obese and Type 2 Diabetic Patients. American Diabetes Association June 2000, abstract #585. Diabetes 2000; 49(S1): A143.

45. Mather KJ, Steinberg HO, Paradisi GC, Quon MJ, Katz A, Hook G, Baron AD. Using the Homeostasis Model (HOMA-IR) To Measure Therapeutically Induced Alterations in Insulin Sensitivity. American Diabetes Association June 2000, abstract #366. Diabetes 2000; 49(S1): A91.

46. Mather KJ, Laakso M, Edelman SV, Hook G, Baron AD. Physiologic Coupling of Skeletal Muscle Metabolism and Blood Flow. American Diabetes Association June 2000, abstract #1840. Diabetes 2000; 49(S1): A435.

47. Mather KJ, Scott RB, Meddings D, Beck P, and Hanley DA. Prevalence of Positive Antiendomysial Antibody Tests for Celiac Disease Among Patients with Idiopathic Osteoporosis. Abstract P3-3, 1999 meeting of the Endocrine Society, June 1999.

48. S. Verma, F. Lovren, C. Triggle, K. Mather, A. Maitland, T. Anderson. Novel Protective Effects of Tetrahydrobiopterin and Bosentan on Endothelial Function in Internal Mammary Arteries and Saphenous Veins From Patients Undergoing Coronary Artery Bypass Graft Surgery. Canadian Cardiovascular Society, Oct 1999.

49. S. Verma, F. Lovren, C. Triggle, K. Mather, A. Maitland, T. Anderson. Novel Protective Effects of Tetrahydrobiopterin and Bosentan on Endothelial Function in Internal Mammary Arteries and Saphenous Veins From Patients Undergoing Coronary Artery Bypass Graft Surgery. American Heart Association, Nov 1999.

50. Mather KJ, Verma S, Anderson TJ. Improved endothelial function with metformin in diet-treated type 2 diabetes mellitus. Canadian Cardiovascular Society, October 1999.

51. Mather KJ, Verma S, Anderson TJ. Effect of modulating insulin resistance on endothelial function in type 2 diabetes mellitus. American Heart Association, November 1999. Circulation 1999;100(18):I-832

52. Mather KJ, Chik C, Corenblum B. A physiologic role for parathyroid hormone-related peptide (PTHrP) during lactation. Abstract P3-81, presented at the 1998 annual meeting of the Endocrine Society June 1998.

53. Mather KJ, Elliott TG, Norman E and Prior JC. Oestrogen and progesterone improve endothelium-dependent vasodilation in postmenopausal women (Abstract). Clin Invest Med 19(4):S25 (1996).

54. Mather K, Burgess E, Ross S, Josefsberg Z. Pattern of office hypertension in non-insulin dependent diabetic patients is different in drug-free versus treatment state. (Abstract) Hypertension Society 1992

38rev. Jan 2012

55. . Mather K, Burgess E, Ross S, Josefsberg Z. Pattern of office hypertension in non-insulin dependent diabetic patients is different in drug-free versus treatment state. (Abstract) Clin Invest Med 15(4);A68 (1992).

Non-refereed1. Mather KJ. Peripheral Vascular Disease. In Clinical Decision Support: Endocrinology,

ed. Thomas A (online textbook at http://www.decisionsupportinmedicine.com). 2012.2. Mather KJ, Baron AD and Quon MJ. Insulin action and endothelial function. In Insulin

Resistance, ed. Reaven GM. (pub. Humana Press). 2008.3. Mather KJ and Baron AD. Vascular Endothelial Dysfunction and Obesity. In Obesity

and Cardiovascular Disease, ed. Robinson MK and Thomas A. (pub. Marcel Dekker Inc.). 2006.

SERVICERefereed

Non-refereed

(Date)

(Signature of Candidate)

39rev. Jan 2012